Document:

EX-10.10

 Exhibit 10.10 

COMPANY - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT 

This Agreement, effective this 27th day of June 2014, between 

TRUSTEES OF DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire, and
being located at Hanover, New Hampshire 03755, hereinafter called Dartmouth, 
 and 

CELDARA MEDICAL, LLC., a company of the State of Delaware, with a principal place of business at 16 Cavendish Court, Centerra Resource Park,
DRTC, Lebanon, NH 03766; hereinafter called Company. 
 WHEREAS, Dartmouth, under the direction of principal investigator Charles
Sentman, Ph.D. has developed new anti-B7-H6 Immunotherapies; and 
 WHEREAS, Dartmouth represents that it has the right to grant
licenses granted in this agreement; and 
 WHEREAS, Company wishes to obtain a license under the terms and conditions hereinafter set forth,
and to use its expertise and resources to manufacture and market the technology; 
 NOW THEREFORE, in consideration of the premises and the
faithful performance of the covenants herein contained, IT IS AGREED: 
 ARTICLE I. Definitions 

Section 1.01 Dartmouth Know-How. “Dartmouth Know-How” shall mean the ideas, methods, characterization and techniques
developed by Dr. Sentman at Dartmouth before the Effective Date, which are necessary for practicing Dartmouth Patent Rights. 

Section 1.02 Dartmouth Patent Rights. “Dartmouth Patent Rights” shall mean Patent Cooperation Treaty Application Serial
No. PCT/US2013/039812, and any United States or Foreign Patents issuing therefrom, and any continuations, continuations-in-part, divisions, reissues, reexaminations or extensions thereof Dartmouth shall be the assignee and owner of all such Patents
and Patent Applications. 
 Section 1.03 Licensed Products. “Licensed Products” shall mean any products or processes
covered by or made, in whole or in part, by the use of Dartmouth Patent Rights or by the use of Dartmouth Know-How. 
 Section 1.04
Field. The “Field” of this Agreement shall mean Human Therapeutics. 
 Section 1.05 Territory. The
“Territory” shall mean worldwide. 

  
 pg. 1 

 Section 1.06 Subsidiary. “Subsidiary” shall mean any other entity or person
that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with, such person or entity, including but not limited to a legal entity at least 50% of the voting stock of which is owned by
Company. 
 Section 1.07 Agreement. “Agreement” shall mean this License Agreement. 

Section 1.08 Net Sales. “Net Sales” shall mean the gross billing price Company, its subsidiaries and sublicensees charge
to their customers for Licensed Products, less sales, use, occupation and excise taxes, and transportation, discounts, returns and allowances in lieu of returns. 

Section 1.09 Effective Date. “Effective Date” shall mean the date first written above and shall be the Effective Date of
this Agreement. 
 Section 1.10 License Year. The “First License Year” shall mean the period commencing on the
Effective Date and ending December 31, 2014. The second and all subsequent “License Years” shall commence on January 1 and end on December 31 of each year. 

Section 1.11 Calendar Quarter. “Calendar Quarter” shall mean the periods ending on
March 31, June 30, September 30 and December 31 of each year. 
 ARTICLE II. Grant 

Section 2.01 License Grant. Dartmouth hereby grants to Company and its Subsidiaries an exclusive, royalty-bearing license
under Dartmouth Know-How and Dartmouth Patent Rights to make, have made, use, modify, exploit, distribute, and/or sell Licensed Products in the Field in the Territory subject to any rights which may be required to be granted to the Government of the
United States of America pursuant to 35 U.S.C. §§200-211. Notwithstanding the foregoing, Dartmouth expressly reserves a non-transferable royalty-free right to use the Dartmouth Patent Rights and Dartmouth Know-How in the Field itself,
including use by its faculty, staff and researchers, for educational and research purposes only. Company agrees that, during the period of exclusivity of this license in the United States, any Licensed Product produced for sale in the United States
will be manufactured substantially in the United States. 
 Section 2.02 Sublicenses. Company shall have the right to grant
sublicenses to third parties under Dartmouth Know-How and Patent Rights to make, have made, use, modify, exploit, distribute, and sell the Licensed Products with the consent of Dartmouth, which consent shall not be unreasonably withheld, except that
such sublicenses shall be in writing and expressly subject to the terms of this Agreement. Company agrees to be responsible for the performance hereunder by its sublicensees. Dartmouth shall have the right to review such sublicenses to assure
conformity with this Section. Upon termination of this Agreement, any such sublicenses will revert directly to Dartmouth. 

  
 pg. 2 

 Section 2.03 Patents. Company shall reimburse Dartmouth for all expenses Dartmouth
has incurred for the preparation, filing, prosecution and maintenance of Dartmouth Patent Rights as of the Effective Date ($18,375.20) in four quarterly installments beginning within thirty (30) days of Company’s receipt of a detailed
invoice. Company shall engage patent attorney(s) acceptable to Dartmouth (“Firm”). Company shall be responsible for future expenses in connection with preparation, filing, prosecution and maintenance of Dartmouth Patent Rights. 

Dartmouth, Company and the Firm shall interact as described in the Client and Billing Agreement (Attachment A). If Company chooses to discontinue prosecution
or maintenance of any United States Patent or Patent Application, which is a subject of Dartmouth Patent Rights, it will so inform Dartmouth within a reasonable time before implementation of such decision. Dartmouth then shall have the right to
prosecute or maintain such Patent or Patent Application on its own and at its own expense, in which case the license to Company under such Patent or Patent Application will terminate. COMPANY shall notify Dartmouth by at least three (3) months
before a National Phase deadline whether it will support the filing of patent applications in particular foreign territories. If COMPANY decides not to support the filing or maintaining foreign applications, Dartmouth reserves the right to file or
maintain such applications on its own, in which case the license to COMPANY in the particular territory will terminate. 
 ARTICLE III.
 
 Disclosure of Invention, Confidentiality and Representations 

Section 3.01 Disclosure of Invention. Dartmouth agrees promptly after the Effective Date of this Agreement to deliver and to
disclose to duly authorized representatives of Company, all proprietary technical data, methods, processes, including the technology, and other information and specifications relating to Dartmouth Know-How. 

Section 3.02 Mutual Confidentiality. Company and Dartmouth realize that some information received by one party from the other
pursuant to this Agreement shall be confidential. It is therefore agreed that any information received by one party from the other, and clearly designated in writing as “CONFIDENTIAL” at the time of transfer, shall not be disclosed
by either party to any third party and shall not be used by either party for purposes other than those contemplated by this Agreement for a period of three (3) years from the termination of the Agreement, unless or until — 

(a) said information shall become known to third parties not under any obligation of confidentiality to the disclosing party, or shall become
publicly known through no fault of the receiving party, or 

  
 pg. 3 

 (b) said information was already in the receiving party’s possession prior to the disclosure
of said information to the receiving party, except in cases when the information has been covered by a preexisting Confidentiality Agreement, or 

(c) said information shall be subsequently disclosed to the receiving party by a third party not under any obligation of confidentiality to the
disclosing party, or 
 (d) said information is approved for disclosure by prior written consent of the disclosing party, or 

(e) said information is required to be disclosed by court order or governmental law or regulation, provided that the receiving party gives the
disclosing party prompt notice of any such requirement and cooperates with the disclosing party in attempting to limit such disclosure. 

Section 3.03 Corporate Action. Dartmouth and Company each represent and warrant to the other party that they have full power and
authority to enter into this Agreement and carry out the transactions contemplated hereby, and that all necessary corporate action had been duly taken in this regard. 

ARTICLE IV. Due Diligence 

Section 4.01 Milestones. Company has represented to Dartmouth, to induce Dartmouth to issue this license, that it will commit
itself to a diligent program of exploiting the Licensed Products so that public utilization will result therefrom. As evidence thereof, Company shall make commercially reasonable efforts to meet the following milestones: 

 

			
	Filing of IND		3 years from the Effective Date
	 Enrollment of first patient into Phase I clinical trial
		8 months after IND filing
	 Enrollment of first patient into Phase II clinical trial
		2 years from start of Phase I
	 Enrollment of first patient into Phase III clinical trial
		1 year after the end of Phase II
	 Filing NDA
		1 year after the end of Phase III
	 FDA approval
		2 years from NDA filing

 Section 4.02 Minimum Royalty. Dartmouth shall have the right, upon thirty (30) days written
notice, to terminate the license, if Company fails to pay Dartmouth a minimum royalty payment of at least: 
 (a) $200,000 after the
completion of the first full calendar year of sales; 
 (b) $800,000 after the completion of the second full calendar year of sales; 

(c) $2,000,000 after the completion of the third full calendar year of sales and after the completion of each full calendar of sales
thereafter. 

  
 pg. 4 

 Company shall have the right to maintain the license by paying Dartmouth within such thirty
(30) day period a cash payment equivalent to the Minimum Royalty. 
 ARTICLE V. Payments, Records and Reports 

Section 5.01 Payments. For the rights and privileges granted under this license, Company shall pay to Dartmouth 

(a) an earned royalty of 2% based on the value of Net Sales of the Licensed Products; and 

(b) non-refundable, non-creditable annual license maintenance fees of $10,000 due upon first anniversary of the Effective Date and $20,000 on
the second anniversary of the Effective Date and on each anniversary thereafter; and 
 (c) following percentages of any consideration,
received from an infringement settlement, less litigation expenditures, as described in Section 8.01, and from each sublicense, except earned royalty on the sale of Licensed Products and verifiable funding to support research and development
activities (e.g., license issue fees, license maintenance fees, lump sum payments in lieu of royalty payments, stocks, etc.) received from each sublicensee of Company for the grant of a sublicense: 

 

			
	 Sublicense agreement executed prior to the 1st anniversary of the Effective
Date
		30%
	 Sublicense agreement executed before filing an IND
		20%
	 Following the first dosing of a patient in a Phase I Clinical Trial and prior to the first dosing of a patient in a Phase II Clinical
Trial
		15%
	 Following the first dosing of a patient in a Phase II Clinical Trial and prior to the first dosing of a patient in a Phase III Clinical
Trial
		10%
	 Following the first dosing of a patient in a Phase III Clinical Trial and prior to the issuance by the FDA (or foreign equivalent) of
approval for marketing of a Licensed Product
		10%
	 After the issuance by the FDA (or foreign equivalent) of approval for marketing of a Licensed Product
		7.5%

  
 pg. 5 

 Dartmouth acknowledges that Company’s business model includes the spin-off of companies, specifically
including the formation of a new legal entity and the transfer of some portion of Company’s assets to the new entity, which may include a sublicense, in which case this provision will not apply. 

(d) non-refundable, non-creditable milestone payments upon achievement of the following events: 

 

					
	 IND filing
		$	50,000	  
	 Phase I Clinical Trial initiation
		$	75,000	  
	 Phase II Clinical Trial initiation
		$	175,000	  
	 Phase III Clinical Trial initiation
		$	300,000	  
	 NDA filing
		$	400,000	  
	 FDA approval
		$	600,000	  

 It is acknowledged that if the milestones are not accomplished by the dates specified in Section 4.01, and Company does
not cure such breach within thirty (30) days of receipt of written notice from Dartmouth, Dartmouth may terminate the license unless payments in the above amounts are made to Dartmouth within thirty (30) days of the dates specified in
Section 4.01. 
 Section 5.02 Reports. Company shall render to Dartmouth: 

(a) within thirty (30) days after the end of each Calendar Quarter a written account of all quantities of Licensed Products subject to
royalty hereunder sold by Company, any Subsidiary, and any sublicensee during such Calendar Quarter, the calculation of royalty thereon, and sufficient data for Dartmouth to verify the calculation, including gross sales and allowable deductions to
derive to Net Sales figures, and shall simultaneously pay in United States dollars to Dartmouth the royalty due with respect to such sales. Conversion of foreign currency to U.S. dollars shall be made at the conversion rate existing in the United
States on the date of royalty payments by Company. Such report shall be certified as correct by an officer of Company. If no Licensed Products subject to royalty hereunder have been sold by Company, its Subsidiaries and its sublicensees during any
such quarter, Company shall so report in writing to Dartmouth within thirty (30) days after the end of said quarter. If royalties for any License Year do not equal or exceed the minimum royalties established in Section 4.02, Company shall
include the balance of the minimum royalty with the payment for the Calendar Quarter ending December 31. Late payments shall be subject to an interest charge of one and one half percent (11/2%) per month. 

(b) within sixty (60) days after the close of each License Year written annual reports which shall include but not limited to: reports of
progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during preceding twelve (12) months as well as plans for coming year. Company shall also provide any reasonable additional data
Dartmouth requires to evaluate Company’s performance. 
 (c) within thirty (30) days of occurrence report of the date of first sale
of Licensed Products in each country. 

  
 pg. 6 

 Section 5.03 Books of Accounts. Company, its Subsidiaries and sublicensees shall keep
full, true and accurate books of accounts and other records containing all particulars which may be necessary for the purpose of ascertaining and verifying the royalties payable to Dartmouth by Company hereunder. Upon Dartmouth’s request,
Company, its Subsidiaries and sublicensees shall permit an independent Certified Accountant selected by Dartmouth (except one to whom Company has some reasonable objection), to periodically have access during ordinary business hours to such records
of Company, its Subsidiaries and sublicensees as may be necessary to determine, for any quarter ending not more than three (3) years prior to the date of such request, the correctness of any report and/or payment made under this Agreement. In
the event that any such inspection shows an underreporting and underpayment in excess of five percent (5%) for any twelve (12) month period, then Company shall pay the cost of such examination. 

ARTICLE VI. Technical Assistance and Commercial Development 

Section 6.01 Technical Assistance. Throughout the term of the Agreement, Dartmouth agrees to permit Company and its designees to
consult with its employees and agents regarding developments and enhancements made subsequent to the Effective Date relating to the Licensed Products, at such times and places as may be mutually agreed upon; provided that Company agrees to make
suitable arrangements with, and to compensate the Dartmouth employees and agents for such consultation. 
 Section 6.02 Commercial
Development. During the term of this Agreement, Company agrees to use commercially reasonable efforts to effectively manufacture and market Licensed Products. Such efforts may include sublicensing, development of promotional literature,
mailings, and journal advertisements. 
 Section 6.03 Name. Neither party shall use nor permit to be used by any other person or
entity the name of the other party nor any adaptation thereof, or the name of either party’s employees not named in this agreement, in any advertising, promotional or sales literature, or for any other purpose without prior written permission
of the other party, except that Company may state that it is licensed by Dartmouth under Dartmouth Know-How and Patent Rights, and Dartmouth may state that it has licensed to Celdara Medical. 

  
 pg. 7 

 ARTICLE VII. Indemnity, Insurance, Disclaimers 

Section 7.01 Indemnity. Company shall defend and indemnify and hold Dartmouth and its trustees, officers, agents and employees
(the “Indemnitees”) harmless from any judgements and other liabilities based upon claims or causes of action against Dartmouth or its employees which arise out of alleged negligence in the development, manufacture or sale of Licensed
Products by Company, its Subsidiaries, and sublicensees, or from the use by the end users of Licensed Products, except to the extent that such judgements or liabilities arise in whole or in part from the gross negligence or willful misconduct of
Dartmouth or its employees, provided that Dartmouth promptly notifies Company of any such claim coming to its attention and that it cooperates with Company in the defense of such claim. If any such claims or causes of action are made, Dartmouth
shall be defended by counsel to Company, subject to Dartmouth’s approval which shall not be unreasonably withheld. Dartmouth reserves the right to be represented by its own counsel at its own expense. 

Section 7.02 Insurance. At such time as any product, process, service relating to, or developed pursuant to, this Agreement is
being commercially distributed or sold (other than for the purpose of obtaining regulatory approvals) by Company or by a sublicensee, Subsidiary or agent of Company, Company shall at its sole cost and expense, procure and maintain comprehensive
general liability insurance in amounts not less than $2,000,000 per incident and naming the Indemnitees as additional insureds. Such comprehensive general liability insurance shall provide (i) product liability coverage and (ii) broad form
contractual liability coverage for Company’s indemnification under this Agreement. If Company elects to self-insure all or part of the limits described above (including deductibles or retentions which are in excess of $250,000 annual aggregate)
such self-insurance program must be acceptable to Dartmouth and Dartmouth Risk Manager. Such insurance will be considered primary as to any other valid and collectible insurance, but only as to acts of the named insured. The minimum amounts of
insurance coverage required shall not be construed to create a limit of Company’s liability with respect to its indemnification under this Agreement. 

Company shall provide Dartmouth with written evidence of such insurance upon request of Dartmouth. Company shall provide Dartmouth with written notice at
least fifteen (15) days prior to the cancellation, non-renewal or material change in such insurance; if Company does not obtain replacement insurance providing comparable coverage within such fifteen (15) day period, Dartmouth shall have
the right to terminate this Agreement effective at the end of such fifteen (15) day period without notice or any additional waiting periods. 
 Company
shall maintain such comprehensive general liability insurance beyond the expiration or termination of this Agreement during (i) the period that any product, process, or service, relating to, or developed pursuant to, this Agreement is being
commercially distributed or sold by Company or by a sublicensee, Subsidiary or agent of Company and (ii) a reasonable period after the period referred to in (i) above which in no event shall be less than fifteen (15) years. 

  
 pg. 8 

 Section 7.03 Disclaimer. Nothing contained in this Agreement shall be construed as:

 (a) a warranty or representation by Dartmouth as to the validity or scope of any Patent Rights; 

(b) a warranty or representation that any Licensed Products manufactured, used or sold will be free from infringement of patents, copyrights,
or rights of third parties, except that Dartmouth represents that it has no knowledge of any existing issued patents or copyrights which might be infringed; 

(c) except as provided in Section 7.01, an agreement to defend against actions or suits of any nature brought by any third parties. 

DARTMOUTH MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AS TO THE 

MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF 

LICENSED PRODUCTS 

ARTICLE VIII. Infringement Matters 

Section 8.01 Infringement by Third Parties. Company shall give Dartmouth prompt notice of any incident of infringement of
Dartmouth Patent Rights coming to its attention. The parties shall thereupon confer together as to what steps are to be taken to stop or prevent such infringement. Dartmouth agrees to use reasonable efforts to stop any such infringement, but shall
not be obliged to commence proceedings against the infringer. If Dartmouth decides to commence proceedings however, Dartmouth shall be responsible for any legal costs incurred and will be entitled to retain any damages recovered. Should Dartmouth
decide not to commence proceedings, Company shall be entitled to do so in its own name against the infringer, in which event Company shall be responsible for all legal costs incurred, without recourse to Dartmouth. Financial recoveries from any such
litigation will first be applied to reimburse Company for its litigation expenditures with additional recoveries being paid to Company, subject to payments due Dartmouth per Sections 5.01(a) and (c). In any action to enforce Dartmouth Patent Rights,
either party, at the request and expense of the other party shall cooperate to the fullest extent reasonably possible. 
 ARTICLE IX.
Duration and Termination 
 Section 9.01 Term. This Agreement shall become effective upon the date first written
above, and unless sooner terminated in accordance with any of the provisions herein, shall remain in full force during the life of the last to expire patents under Dartmouth Patent Rights contemplated by this agreement in the last to expire
territory. If mutually desired, the parties may negotiate for an extension of this License. Upon the termination of the Agreement Company shall have the right to sell the remainder of the Licensed Product on hand, provided the sales will be subject
to the royalty payments of this Agreement. 

  
 pg. 9 

 Section 9.02 Termination - Breach. In the event that either party defaults or
breaches any of the provisions of this Agreement, the other party shall have the right to terminate this Agreement by giving written notice to the defaulting party, provided, however, that if the said defaulting party cures said default within
thirty (30) days after said notice shall have been given, this Agreement shall continue in full force and effect. The failure on the part of either of the parties hereto to exercise or enforce any right conferred upon it hereunder shall not be
deemed to be a waiver of any such right nor operate to bar the exercise or enforcement thereof at any time or times thereafter. 

Section 9.03 Termination at Will. Company shall have the right to terminate this Agreement by giving three (3) months advance
written notice to Dartmouth to that effect and paying atermination fee of $2,500. Upon termination, a final report shall be submitted and royalty and other payments due under Article V, as well as unreimbursed patent expenses due Dartmouth become
immediately payable. Upon receipt of the termination notice, Dartmouth shall be free to start negotiations with a Third Party for the rights granted herein. 

Section 9.04 Insolvency. In the event that Company shall become insolvent, shall make an assignment for the benefit of creditors,
or shall have a petition in bankruptcy filed for or against it, the Agreement shall terminate. 
 Section 9.05 Prior Obligations and
Survivability. Termination of this Agreement for any reason shall not release either party from any obligation theretofore accrued. Sections 3.02, 5.01 – 5.03, 7.01 – 7.03, 9.03, 10.01 – 10.09 shall survive the termination of this
Agreement. 
 ARTICLE X. Miscellaneous 

Section 10.01 Governing Law. This Agreement shall be construed, governed, interpreted and enforced according to the laws of the
State of New Hampshire. 
 Section 10.02 Notices. Any notice or communication required or permitted to be given by either party
hereunder, shall be deemed sufficiently given, if mailed by certified mail, return receipt requested, and addressed to the party to whom notice is given as follows: 
  

			
	If to Company, to:		
		
			Jake Reder
			CEO
			Celdara Medical, LLC.
			16 Cavendish Ct., Centerra Resource Park, DRTC
			Lebanon, NH 03766
		
	If to Dartmouth, to:		
		
			Alla Kan
			Director
			Technology Transfer Office
			Dartmouth College
			11 Rope Ferry Road
			Hanover, NH 03755

  
 pg. 10 

 Section 10.03. Assignment. Dartmouth acknowledges that Company’s business model
includes the spin-off of companies, specifically including the formation of a new legal entity and the transfer of some portion of Company’s assets to the new entity which may include Assignment of this Agreement. Beyond this exception, neither
party shall assign or transfer this Agreement without the express prior written consent of the other, which shall not be unreasonably withheld. For purposes of this Agreement, an assignment or transfer of this Agreement by COMPANY shall be deemed to
occur in connection with (a) an express assignment or transfer, (b) a general assignment for the benefit of creditors or in connection with any bankruptcy or other debtor relief law, (c) any merger or consolidation to which COMPANY is
a party, regardless of whether COMPANY is the surviving corporation, or (d) any other transaction pursuant to which a change would occur in the “ultimate parent entity” of COMPANY, applying the rules in effect from time to time under
the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. 
 Section 10.04 Entire Agreement. This Agreement
represents the entire Agreement between the parties as of the effective date hereof, and may only be subsequently altered or modified by an instrument in writing. This agreement cancels and supersedes any and all prior oral or written agreements
between the parties which relate to the subject matter of this Agreement. 
 Section 10.05 Mediation and Arbitration. Both
parties agree that they shall attempt to resolve any dispute arising from this Agreement through mediation. Both parties agree that at least one employee, capable of negotiating an agreement on behalf of his employer, shall, within three weeks of
receipt of written notification of a dispute, meet with at least one employee of the other party who is also capable of negotiating an agreement on behalf of his employer. If no agreement can be reached, both parties agree to meet again within a
four week period after the initial meeting to negotiate in good faith to resolve the dispute. If no agreement can be reached after this second meeting, both parties agree to submit the dispute to binding arbitration under the Rules of the American
Arbitration Association before a single arbitrator. 
 Section 10.06 Waiver. A failure by one of the parties to this Agreement
to assert its rights for or upon any breach or default of this Agreement shall not be deemed a waiver of such rights nor shall any such waiver be implied from acceptance of any payment. No such failure or waiver in writing by any one of the parties
hereto with respect to any rights, shall extend to or affect any subsequent breach or impair any right consequent thereon. 

  
 pg. 11 

 Section 10.07 Severability. The parties agree that it is the intention of neither
party to violate any public policy, statutory or common laws, and governmental or supranational regulations; that if any sentence, paragraph, clause or combination of the same is in violation of any applicable law or regulation, or is unenforceable
or void for any reason whatsoever, such sentence, paragraph, clause or combinations of the same shall be inoperative and the remainder of the Agreement shall remain binding upon the parties. 

Section 10.08 Marking. Company agrees to mark the Licensed Products with all applicable trademarks, and patent numbers. 

Section 10.09 Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not
constitute a part hereof. 
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement, in duplicate originals, by their
respective officers hereunto duly authorized, the day and year herein written. 
  

					
	THE TRUSTEES OF DARTMOUTH COLLEGE
			
			By		 /s/ Alla Kan

			
			Date		June 27, 2014
			
			Name		Alla Kan, Director
			Title		Technology Transfer Office
	
	CELDARA MEDICAL, LLC
			
			By:		 /s/ Jake Reder

			
			Date		Jul 8, 14
			
			Name		Jake Reder
			Title		CEO

  
 pg. 12 

 Attachment A: Client and Billing Agreement 

Reference Doc: Procedures to be Followed by LeclairRyan in Regard to Licensed Dartmouth Patent Rights 

  
 pg. 13 

 FIRST AMENDMENT TO 

CELDARA - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT 

THIS FIRST AMENDMENT (the “First Amendment”) is effective as of January 4, 2015, by and between the TRUSTEES OF
DARTMOUTH COLLEGE, a non-profit educational and research institution existing under the laws of the State of New Hampshire (hereinafter “Dartmouth”) and Celdara Medical, LLC having its principal place of business at 16 Cavendish
Court, Centerra Resource Park, DRTC, Lebanon, NH 03766 (hereinafter “Celdara”). 
 WHEREAS, the parties previously
entered into an Exclusive License Agreement, dated June 27th, 2014 (the “Agreement”) (capitalized terms used but not otherwise defined in this First Amendment shall have the
meanings given such terms in the Agreement); 
 WHEREAS, the parties wish to amend the Agreement in the manner set forth in
this First Amendment and otherwise to provide for certain agreements by the parties as set forth herein; 
 NOW, THEREFORE, in
consideration of the premises and the covenants herein contained, the parties hereby agree to amend the Agreement as follows: 
 1.
Section 1.03 is hereby amended and restated in its entirety as follows: 
 “Section 1.03 Licensed
Products, “Licensed Products” shall mean any product or process, the manufacture, use or sale of which, in whole or in part, is covered by the Dartmouth Patent Rights.” 

2. Section 5.01(c) is hereby amended and restated in its entirety as follows: 

“(c) following percentages of any consideration received by the Company from an infringement settlement, less litigation expenditures, as
described in Section 8.01, or received by the Company from each sublicensee of the Company for the grant of a sublicense hereunder with respect to any Licensed Products (e.g. license issue fees, license maintenance fees, etc.), except earned
royalty on the sale of any Licensed Products: 
 (i) 15% if such sublicense is granted by the Company during the preclinical development
stage of such Licensed Product up to administration of the first dose in a Phase I clinical trial for such Licensed Product; 
 (ii) 10% if
such sublicense is granted by the Company after the administration of the first dose in a Phase I clinical trial for such Licensed Product and prior to completion of a Phase II clinical trial for such Licensed Product; or 

(iii) 5% if such sublicense is granted by the Company after the completion of a Phase II clinical trial for such Licensed Product and
thereafter.” 

  
 1 

 3. Section 6.02 is hereby amended and restated in its entirety as follows::

 “Section 6.02 Commercial Development. During the term of this Agreement, the Company will use commercially reasonable efforts
to achieve the milestone targets set forth herein. These efforts will include use of commercially reasonable efforts to develop and commercialize Licensed Products. Company will use commercially reasonable efforts to maintain or cause to be
maintained by the Company a bona fide, fully funded, fully staffed ongoing and active research, development, manufacturing, regulatory, business development, marketing and sales effort to make the Licensed Products commercially available as
soon as commercially practicable.” 
 6. Except as specifically amended by this First Amendment, the terms and conditions of the
Agreement shall remain in full force and effect. 
 7. This First Amendment shall be construed, governed, interpreted and enforced according
to the laws of the State of New Hampshire. 
 8. This First Amendment may be executed in two or more counterparts, each of which shall be
deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this First Amendment by facsimile or by email of a scanned copy will be effective as delivery of
an original executed counterpart of this First Amendment. 
 IN WITNESS WHEREOF, the parties have duly executed this First Amendment in duplicate
originals, by their respective officers hereunto duly authorized, as of the date herein written. 
  

									
	CELDARA MEDICAL, LLC				TRUSTEES OF DARTMOUTH COLLEGE
					
	By:		 /s/ Jake Reder
				By:		 /s/ Glennis Gold

	Name:		Jake Reder, Ph.D.				Name:		Glennis Gold, Interim Director
	Title:		CEO				Title:		Technology Transfer Office

  
 2EX-10.11

 Exhibit 10.11 
 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 
 TECHNOLOGY LICENSE
CONTRACT 
 Article 1.00 - Preliminary Provisions. 
 1.01 EFFECTIVE DATE. The effective date of this contract is June 4, 2007 
 1.02 PARTIES.
There are two parties to this contract (together called “the Parties” or individually “a Party”). They are: 
  

	(a)	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (called
“MAYO” in this contract), and 

  

	(b)	 Cardio3 BioSciences, a Belgian company in the process of being created, located at Boulevard de France 9, 1420 Braine l’Alleud, Belgium (called the “COMPANY” in this contract).

 1.03 PURPOSE OF CONTRACT. Certain inventions have been made in connection with MAYO’s research, patient care,
and education programs. By assignment of the inventions from the inventors, MAYO owns certain patent-rights, and know-how. MAYO intends to grant licenses to use its patent rights, and know-how for the development of products, processes, and methods
for public use and benefit. The COMPANY intends to develop marketable products, processes, and methods for public use and benefit within the Territory described in this contract, by using the Licensed Invention and Licensed Know-How. Both parties
acknowledge that MAYO has carefully selected the COMPANY because of the COMPANY’s best suited characteristics which make the COMPANY especially suitable as a licensee of the invention. The COMPANY enters this licensing contract with MAYO for
use of the Licensed Invention, patent rights, and Know-How on an exclusive basis, subject only: (a) to MAYO’s right to make, have made, and use the Licensed Invention and Know-How on a royalty-free basis within its and its Affiliates’
own programs; and (b) to the rights, if any, of the United States government. 
 Article 2.00 - Definitions.

 2.01 LICENSED INVENTION means Cardiogenic Cocktail for Production of Cardiac Cells (MAYO reference number MMV# 2004-182). If not
patented, then the Licensed Invention is MAYO’s trade secret. This definition also includes licensed patent rights under pending PCT Patent Application Serial No. US2005/026800, filed July 29, 2005, and any divisions, continuations, and
continuations-in-part based thereon, and any patents which may issue therefrom, and any reissues or extensions thereof. 
 2.02 AFFILIATE
for Mayo shall mean, any corporation or other entity within the same “controlled group of corporations” as Mayo or its parent, Mayo Clinic. For purposes of this definition, the term “controlled group of corporations” will
have the same definition as section 1563 of the Internal Revenue Code as of November 10, 1998, but will include corporations or other entities which if not a stock corporation, more than 50% of the board of directors or other governing body of
such corporation or other entity is controlled by a corporation within the controlled group of corporations of MAYO or Mayo Clinic. Mayo’s Affiliates include, but are not limited to: Mayo Clinic; Mayo Collaborative Services, Inc.; Rochester
Methodist Hospital; Saint Marys Hospital; Mayo Clinic Rochester; Mayo Clinic Jacksonville; St. Luke’s Hospital Association; Mayo Clinic Arizona; and its Mayo Health System entities. 
 2.03 FIELD OF USE means treatment of embryonic and autologus mesenchymal stem cells to guide development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease,
ischemic and non-ischemic cardiomyopathy. 

  
 -Page 1 of 10-

 2.03 FIELD OF USE means treatment of embryonic and autologus mesenchymal stem cells to guide
development into cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy. 

2.04 QUARTER begins on the date in Section 1.01 of this contract, and thereafter begins on the first day of each January, April, July,
and October during the term of this contract. 
 2.05 YEAR begins on the date in Section 1.01 of this contract, and
thereafter begins on the first day of each January during the term of this contract. 
 2.06 LICENSED KNOW-HOW means trade secrets
including technical information, whether or not patentable, including but not limited to engineering, scientific, and practical information and formulas; information about qualities, uses, and sales methods and procedures; information about
materials and sources; blueprints, drawings, specifications, and other relevant writings used in the design, manufacture, and sale of products, processes, and methods in connection with the Licensed Invention. 

2.07 MAYO INFORMATION means all information embodied in the Licensed Invention, and Licensed Know-How, or expressly marked, labeled,
referenced in writing, which is disclosed to the COMPANY by MAYO, relating in any way to MAYO’s markets, customers, patents, inventions, products, procedures, designs, plans, organization, employees, or business in general, but not including:

  

	(a)	information which, before disclosure becomes part of the public domain through no action or fault of the COMPANY; or 

 

	(b)	information which the COMPANY can show was in its possession before disclosure by MAYO to the COMPANY and was not acquired, directly or indirectly, from MAYO; or

  

	(c)	information which was received by the COMPANY from a third party having a legal right to transmit such information. 

2.08 TERMINATION of this contract means the ending, expiration, rescission, or any other discontinuation of this contract for any reason
whatsoever. 
 2.09 TERRITORY means the world. 
 Article 3.00 - Grant of Rights. 
 3.01 GRANT. Subject only to the exceptions
described in Section 1.03 of this contract, MAYO grants to the COMPANY an exclusive license to make, have made, use, modify, enhance, promote, market and/or sell the Licensed Invention whether or not patented, and a non-exclusive right to use
the Licensed Know-How, in the Territory within the Field of Use, according to the terms of this contract. The Licensed Invention and Know-How, if not patented, are trade secrets of MAYO. 
 3.02 PURCHASE AT COST. MAYO may, at its sole option, purchase the Licensed Invention in any quantity at cost from the COMPANY, and use the Licensed Know-How without cost to MAYO, exclusively within
MAYO’s and its Affiliates’ own programs provided such programs are only for internal (research or clinical) use and do not include any allocation of right to any third party neither any sale or marketing of products derrivated from the
Licensed Invention. No Royalty will be due to MAYO for these sales to MAYO. 
 3.03 DISCLOSURE OF KNOW-HOW. Within one month after
execution of this contract, MAYO shall make available to the COMPANY the Licensed Know-How. MAYO, however, owns the materials in which the Licensed Know-How is embodied, including, but not limited to, prototypes, blueprints, and plans. The COMPANY
shall have the right to confer with the inventors (so long as they are employees of MAYO or its Affiliates) for a reasonable period and at such times that are mutually convenient. 

  
 -Page 2 of 10-

 3.04 Confidential Information’’ means any and all information, data, results, Inventions,
trade secrets, techniques, material, or compositions of matter of any type or kind, including without limitation all know-how and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, personnel, financial, legal and
commercial information or data, whether communicated in writing, orally or by any other method, that a Party treats or identifies as confidential and, in each case, is disclosed by one Party to the other Party with respect to such disclosing
Party’s rights or obligations under this contract. 
 3.04.01 Nondisclosure Obligation 

(a) Confidential Information. All Confidential Information shall be maintained in confidence by the receiving Party and shall not
be disclosed to any non-Party (N.B. subcontractor free lance associates are not covered - see D) or used for any purpose except to exercise its rights and perform its obligations under this contract without the prior written consent of the
disclosing Party, except to the extent that the receiving Party can demonstrate by competent written evidence that such Confidential Information: 
 (i) is known by the receiving Party at the time of its receipt and, not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; 

(ii) is in the public domain other than as a result of any breach of this Agreement by the receiving Party; 

(iii) is subsequently disclosed to the receiving Party on a non-confidential basis by a third party who may lawfully do so; or

 (iv) is independently discovered or developed by the receiving Party without the use of Confidential Information
provided by the disclosing Party, as documented by the receiving Party’s records. 
 (b) Return of Confidential
Information Upon Expiration or Termination of contract. Within thirty (30) days after any expiration or termination of this contract, each Party shall destroy (and certify to the other Party such destruction) or return (as requested by the
other Party) all Confidential Information provided by the other Party except as otherwise set forth in this contract, and except that each Party may retain a single copy of the Confidential Information in its confidential legal files for the sole
purpose of ascertaining its ongoing rights and responsibilities regarding the Confidential Information. 
 3.04.02
Permitted Disclosures 
 (a) Permitted Disclosure. Each Party may disclose Confidential
Information provided by the other Party to the extent such disclosure is reasonably necessary in the following instances: 

(i) disclosure to governmental or other regulatory agencies in order to obtain patents, or to gain or maintain approval to conduct
clinical trials or to market Licensed Invention (in each case to the extent permitted by this contract), but such disclosure may be only to the extent reasonably necessary to obtain patents or authorizations; 

  
 -Page 3 of 10-

 (ii) complying with applicable court orders or governmental regulations, including
without limitation rules or regulations of the Securities and Exchange Commission, or by rules of the National Association of Securities Dealers, any securities exchange or NASDAQ; provided, however, that the receiving Party shall first have given
notice to the other Party hereto in order to allow such Party the opportunity to seek confidential treatment of the Confidential Information; 
 (iii) disclosure to consultants, agents or other third parties solely to the extent required to accomplish the purposes of this contract or in connection with due diligence or similar
investigations by such third parties, and disclosure to potential third party investors in confidential financing documents, in each case on the condition that such third parties agree to be bound by confidentiality and non-use obligations at least
equivalent in scope to those contained in this contract or for the purposes of such financing; provided the term of confidentiality for such third parties shall expire no less than three (3) years after the expiry or earlier termination of this
contract. 
 (b) Written Agreements. Each Party shall have in effect a policy requiring or obtain written agreements from
each of its employees, consultants and contractors who perform work on the Sponsored Research Program, which agreements shall obligate such persons to similar obligations of confidentiality and to assign to such Party all know-how, information and
Inventions conceived, made or reduced to practice by such persons during the course of performing the Sponsored Research Program. Each Party will notify the other Party promptly upon discovery of any unauthorized use or disclosure of the
Confidential Information of the other Party. 
 (c) Required Disclosure. If a Party is required by judicial or
administrative process to disclose Confidential Information that is subject to the non-disclosure provisions of Section 3.04.1, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the
other Party an opportunity to challenge or limit the disclosure obligations. Each Party shall provide reasonable cooperation to the other Party in any such process. Confidential Information that is disclosed by judicial or administrative process
shall remain otherwise subject to the confidentiality and non-use provisions of this article 3.04, and the Party disclosing Confidential Information pursuant to law or court order shall take all reasonable steps necessary, including without
limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such Confidential Information. 
 3.04.03 Publication. If a Party, its employees or consultants wishes to make a written publication or oral presentation related to a Licensed Invention, that
Party shall deliver to the non-publishing Party a copy of the proposed written publication or an outline of an oral disclosure at least thirty (30) days prior to submission for publication or presentation. The non-publishing Party shall have
the right to review and propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable delay in publication or presentation in order to protect patentable
information. If the non-publishing Party requests modifications to the publication or presentation, the Party wishing to make such written publication or oral presentation shall edit such publication or presentation to prevent disclosure of trade
secret or proprietary business information of the non-publishing Party prior to submission of the publication or presentation, and/or delay such publication or presentation. 
 3.04.04 Publicity/Use of Names 
 (a) General. Either Party
shall be free to disclose, without the other Party’s prior written consent, the existence of this contract, the identity of the other Party and those terms of the contract which have already been publicly disclosed in accordance herewith.

 (b) Trademarks. Except as set forth in Section 3.04.04(a), or as expressly permitted by this contract, neither
Party shall use the name, trademark, trade name or logo of the other Party or its employees, including in any publicity, news release or disclosure relating to this contract or its subject matter, without the prior express written permission of the
other Party. 

  
 -Page 4 of 10-

 (b) Protection of Interests. The Parties will use commercially reasonable efforts to
ensure that the content of any oral statement or written disclosure or publication will comply with applicable laws and regulations and will not adversely affect the Parties’ commercial interests. 

Article 4.00 - Consideration and Royalties. 
 4.01 CONSIDERATION. The license Grant under this contract will be remunerated with an initial royalty, which is nonrefundable and amounts to € 9,500,000.00. No other royalties will be
due 
 4.02 TAXES. Unless in case of purchase at cost (see section 3.02 hereabove) the COMPANY is responsible for all taxes (other than
net income taxes), duties, import deposits, assessments, and other governmental charges, however designated, which are now or hereafter will be imposed by any authority in or for the Territory, (a) by reason of the performance by MAYO of its
obligations under this contract, or the payment of any amounts by the COMPANY to MAYO under this contract; (b) based on the Licensed Invention or use of the Licensed Invention; or (c) which relate to the import of the Licensed Invention
into the Territory. 
 4.03 NO DEDUCTIONS. All payments to be made by the COMPANY to MAYO under this contract represent net amounts MAYO
is entitled to receive, and shall not be subject to any deductions or offsets for any reason whatsoever. If such payments become subject to taxes, duties, assessments, or fees of any kind levied in the Territory, such payments from the COMPANY shall
be increased to the extent that MAYO actually receives the net amounts due under this contract. 
 4.04 U.S. CURRENCY. All payments to
MAYO under this contract shall be made by draft drawn on a United States bank, and payable in United States dollars 
 Article
5.00 Research 
 5.01 RESEARCH FUNDING Beginning in 2008, and for a total of three years. COMPANY will contribute to research funding
at MAYO in the amount of $ 742.500 per year. The research projects hereto related will be documented in advance with a project plan and budget which will be proposed by MAYO mutually agreed after discussion out of good faith among the parties.
These projects plans shall include specific aims and deliverables to be reasonably acceptable to the Company. In this context, payments will be made in four equal quarterly installments of $ 185,625 payable at the beginning of each relevant quarter.
Any improvement developed in the course of work under any of these projects plans will fall under the license Grant in this contract. MAYO will report any research findings under this Section 5.01 to the COMPANY on a quarterly basis
(hereinafter “the Sponsored Research”). 
 5.02 COMPANY DIRECTED RESEARCH In addition to the research under Section 5.01,
MAYO and COMPANY will develop a budget, timeline and list of specific deliverables for any research that the COMPANY and MAYO desire to perform. 
 5.03 PURCHASE OF EQUIPMENT COMPANY will pay MAYO $337,000 to be used to purchase equipment to be used for the Sponsored Research described in Sections 5.01 and 5.02. This equipment may be used for
other research at MAYO but preference will be given to any project funded by COMPANY. This payment is due no later than March 15, 2008 

  
 -Page 5 of 10-

 Article 6.00 - Warranties and Indemnification. 

6.01 Mayo represents and warrants to COMPANY that to the best of Mayo’s internal patent counsel’s knowledge, no third party has sent
written notice to Mayo that practice of the Licensed Invention infringes on any third party’s intellectual property rights. 
 6.02 USE OF NAME AND LOGO. The COMPANY shall not use publicly for publicity, promotion, or otherwise, any logo, name, trade name, service mark, or trademark of MAYO or its Affiliates,
including, but not limited to, the terms “Mayo®,” “Mayo Clinic®,” or any simulation, abbreviation, or adaptation of the same, or the name of any MAYO employee or agent,
without MAYO’s prior, written, express consent. MAYO may withhold such consent in MAYO’s absolute discretion. 
  

	6.03	MAYO PATENTS. Except as expressly provided in this contract, nothing shall be construed 

 

	(a)	a warranty or representation by MAYO as to the validity or scope of any patents contained in the Licensed Invention; 

 

	(b)	an obligation to bring or to prosecute actions against third parties for infringement of patent 

 

	(c)	conferring by implication, estoppel, or otherwise any patents of MAYO. 

 6.04 WARRANTIES. MAYO HAS NOT MADE AND PRESENTLY MAKES NO PROMISES, GUARANTEES, REPRESENTATIONS OR WARRANTIES OF ANY NATURE, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, REGARDING THE
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SUITABILITY, DURABILITY, CONDITION, QUALITY, OR ANY OTHER CHARACTERISTIC OF THE LICENSED INVENTION. THE COMPANY TAKES THE LICENSED INVENTION “AS IS,” “WITH ALL EVENTUAL TECHNICAL
FAULTS,” AND “WITH ALL EVENTUAL DEFECTS,”. 
 6.05 INDEMNIFICATION. the COMPANY will defend, indemnify, and hold harmless
MAYO and MAYO’s Affiliates from any and all third party claims, actions, demands, judgments, losses, costs, expenses, damages and liabilities (including but not limited to reasonable attorneys fees and other expenses of litigation), regardless
of the legal theory asserted, arising out of or connected with: 
  

	(a)	use by the COMPANY of Patent Rights or information furnished or licensed under this Agreement; 

 

	(b)	design, manufacture, distribution, use, sale, or other disposition of Products, including Licensed Products, by the COMPANY or its transferees; and

  

	(c)	any obligation of COMPANY hereunder. 

 As used
in Sections 6.04 and 6.05, MAYO and its Affiliates include the trustees, officers, agents, and employees of MAYO and its Affiliates. The parties agree that the indemnity stated in this Section 5.04 should be construed and applied in favor of
indemnification. COMPANY will, during the Term, carry insurance at a level commensurate with their obligation to indemnify MAYO. In any case, prior to any use in humans, COMPANY will carry occurrence-based liability insurance, including products
liability and contractual liability, in an amount and for a time period sufficient to cover the liability assumed by COMPANY hereunder, such amount being at least one million US dollars ($ 1,000,000). Notwithstanding the foregoing, COMPANY shall
not, without MAYO’s prior written consent, settle or compromise any Claim in a manner that would require MAYO to admit liability or incur financial obligation. MAYO may be represented by counsel of its own choosing, at its own expense.

  
 -Page 6 of 10-

	6.06	ADDITIONAL WAIVERS. THE COMPANY AGREES THAT MAYO SHALL NOT BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY DELAY IN FURNISHING PRODUCTS OR SERVICES, OR ANY OTHER
PERFORMANCE UNDER THIS CONTRACT, UNLESS RESULTING FROM MAYO’S NEGLIGENCE OR WILLFULL AND WANTON MISCONDUCT. 

 IN NO EVENT
SHALL PARTIES’ LIABILITY OF ANY KIND INCLUDE ANY SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF THE BREACHING PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. IN NO CASE SHALL PARTIES LIABILITY FOR DAMAGES
OF ANY TYPE EXCEED THE DOUBLE OF TOTAL ROYALTIES WHICH HAVE ACTUALLY BEEN PAID TO MAYO BY THE COMPANY AS OF THE DATE OF FILING OF THE ACTION AGAINST MAYO WHICH RESULTS IN THE SETTLEMENT OR AWARD OF DAMAGES. 

Article 7.00 - Term and Termination. 
 7.01 TERM. The term of this contract is for the longer of 10 years, or for the life of the last of any patents that may be related to the Licensed Invention. 

7.02 TERMINATION. 
  

	a)	If the COMPANY defaults in the payment of any fees, or payment, or in the making of any report; or makes a false report MAYO may, at its sole option, terminate this
contract upon written notice to the COMPANY, Termination being effective upon thirty (30) days after mailing or personal delivery unless such default or other breach is first cured. 

 

	b)	MAYO may terminate this license at any time after January 2011 if MAYO, has reasonable evidence that the COMPANY does not intend to develop the Licensed Invention
commercially. MAYO and the COMPANY will first try to resolve the disagreements in good faith. Should the disagreements remain, MAYO and the COMPANY agree to binding arbitration as to the validity of the evidence. 

7.03 CHALLENGE BY OR INSOLVENCY OF COMPANY. MAYO may terminate this contract immediately upon written notice to the Company if the Company ceases
conducting business in the normal course, becomes insolvent or bankrupt, makes a general assignment for the benefit of creditors, admits in writing its inability to pay its debts as they are due, permits the appointment of a receiver for its
business or assets, or avails itself of or becomes subject to any proceeding under any statute of any governing authority relating to insolvency or the protection of rights of creditors. 

 

	7.04	INFRINGEMENT OF THIRD PARTY RIGHTS. 

 MAYO
should upon first demand of COMPANY execute a specific license agreed with said third party in order to safeguard COMPANY’s use of the Licensed Invention under this contract. MAYO should bear all costs hereto related. 

7.05 SURVIVAL. The following obligations survive the Termination of this contract: 

 

	(a)	the COMPANY’s obligation to supply reports covering the time period up to the date of Termination; 

 

	(b)	MAYO’s right to receive payments, fees, and royalties (including minimum royalties) accrued or accruable from payment at the time of any Termination;

  
 -Page 7 of 10-

	(c)	the COMPANY’s obligation to maintain records, and MAYO’s right to have those records inspected; 

 

	(d)	any cause of action or claim of MAYO, accrued or to accrue, because of any action or omission by the COMPANY; 

 

	(e)	the COMPANY’s obligations stated in Sections 3.04, 6.02 and 6.05 of this contract; and 

 

	(f)	unless if terminated pursuant to section 7.02, the COMPANY’s obligation to return all materials given to it by MAYO, including inventory. 

Article 8.00 - Best Efforts. 
 8.01 REPRESENTATIONS OF THE COMPANY. The COMPANY has represented to MAYO, to induce MAYO to enter into this contract, that the COMPANY is experienced in the development, production, quality
control, service, manufacture, marketing, and sales of products similar to the Licensed Invention, and that it will commit itself to a thorough, vigorous, and diligent program of marketing the Licensed Invention. COMPANY also represents to MAYO that
all product sold in the United States will be manufactured substantially in the United States. 
 8.02 COMPANY EFFORTS. If at any time
during the term of this contract, the COMPANY is not exercising, or is presently unable to exercise, its best efforts in the development, production, quality control, service, manufacture, marketing, or sales of the Licensed Invention, then MAYO may
terminate the exclusivity of this contract immediately upon written notice to the COMPANY. The criteria MAYO may use in reaching such a conclusion include, but are not limited to, the loss for any reason of key personnel from the COMPANY, and the
present or projected financial status of the COMPANY. 
 8.03 MAYO EFFORTS If at any time during the term of this contract, MAYO is
clearly not exercising, or is presently unable to exercise, reasonable efforts in the execution of this contract, COMPANY will promptly notify MAYO of any specific actions or inactions that indicate such lack of effort. If Mayo does not reasonably
cure within 120 days, COMPANY will no longer be obliged to pay any outstanding research funding upon written notice to MAYO. 

Article 9.00 - Patents. 

9.01 PATENT NUMBERS. The COMPANY shall mark all Licensed Invention units sold in the United States with any applicable United States patent
numbers, and all Licensed Invention units sold in countries other than the United States with any applicable patent numbers of the country of sale. All Licensed Invention units shipped to or sold in other countries in the Territory shall be marked
in such a manner as to conform with the patent laws and other laws of the country of manufacture or sale. 
 9.02 INFRINGEMENT BY THIRD
PARTY. Notwithstanding anything else in this contract, if at any time a third party shall infringe any unexpired licensed patent right licensed in this contract, and if such infringement shall come to the attention of either MAYO or the COMPANY,
that party shall promptly give notice in writing to the other party of the existence of such infringement, and the parties to this contract shall, upon mutual agreement, decide on an appropriate course of action to take against the infringer in view
of all of the circumstances then existing. MAYO shall not unreasonably withhold such agreement. 
 9.03 PATENTS. The COMPANY shall pursue
patent coverage and maintain patents for the Licensed Invention at its own expense. Any patents resulting from the Licensed Invention or based upon the Licensed Invention shall be applied-for on behalf of MAYO if invented by MAYO, assigned to the
COMPANY if invented by the COMPANY and jointly assigned if jointly invented. 

  
 -Page 8 of 10-

 Article 10.00 - General Provisions. 

10.01 ASSIGNMENT AND SUBCONTRACT. The COMPANY is strictly prohibited from assigning or subcontracting any of its obligations or rights under this
contract without MAYO’s prior, express, written consent, which consent may not be unreasonably withheld. 
 10.02 WAIVER. No
part of this contract may be waived except by the further written agreement of the parties. Forbearance in any form from demanding the performance of a duty owed under this contract is not a waiver of that duty. Until complete performance of a duty
owed under this contract is accomplished, the party to which that duty is owed may invoke any remedy under this contract or under law, despite its past forbearance in demanding performance of that duty. 

10.03 GOVERNING LAW AND JURISDICTION. This contract is made and performed in Minnesota. It is governed by Minnesota law, but specifically not
including Article 2 of the Uniform Commercial Code as enacted in Minnesota. This is not a contract for the sale of goods. In addition, no Minnesota conflicts-of-law or choice-of-laws provisions apply to this contract. To the extent the substantive
and procedural law of the United States would apply to this contract, it supersedes the application of Minnesota law. [The exclusive fora for actions between the parties in connection with this contract are the State District Court sitting in
Olmsted County, Minnesota, or the United States Court for the District of Minnesota.] 
 10.04 HEADINGS. The headings of articles and
sections used in this document are for convenience of reference only, and are not a part of this contract. 
 10.05 NOTICES. Any
notice required to be given under this contract is properly provided if in writing and either personally delivered, or sent by express or certified mail, postage prepaid, to the parties at the following addresses, unless other addresses are provided
consistent with this Section 10.5: 
 Mayo Foundation for Medical Education and Research 

200 First Street SW 
 Rochester, Minnesota
55905-0001 
 Attn: Office of Technology Commercialization, Mayo Medical Ventures 

Cardio3
 BioSciences (in the process of being created) 
 Boulevard de France 9

 1420 Braine l’Alleud 
 Unless
otherwise expressly specified in this contract, notices sent by mail are considered effective upon the earlier of: the fifth (5th) day after dispatch (or the tenth (10th) day after dispatch if dispatched by air mail other than in the
United States) or the day of actual receipt. Notices personally delivered are considered effective upon the date of delivery. It is the responsibility of the party giving notice to obtain a receipt for delivery of the notice, if that party considers
such a receipt advisable. 
 10.06 LIMITATION OF RIGHTS CREATED. This contract is intended only to benefit the two parties to it.
They have no intention to create any interests for any other party. Specifically, no interests are intended to be created for any customer, patient, research subjects, or other persons (or their relatives, heirs, dependents, or personal
representatives) by or upon whom the Licensed Invention may be used. 

  
 -Page 9 of 10-

 10.07 INDEPENDENT CONTRACTORS. In the performance of their respective duties under this contract, the
parties are independent contractors of each other. Neither is the agent, employee, or servant of the other. Each is responsible only for its own conduct 
 10.08 ENTIRE CONTRACT. This document states the entire contract between the parties about its subject matter. All past and contemporaneous discussions, agreements, proposals, promises, warranties,
representations, guarantees, correspondence, and understandings, whether oral or written, formal or informal, are entirely superseded by this contract. 
 10.09 UNENFORCEABLE PROVISION. The unenforceability of any part of this contract will not affect any other part. This contract will be construed as if the unenforceable parts had been omitted.

 10.10 CHANGES TO CONTRACT. No part of this contract, including this Section 10.10, may be changed except in writing, through
another document signed by both parties. 
 10.11 CONSTRUCTION. Both parties agree to all of the terms of this contract. Both parties
execute this contract only after reviewing it thoroughly. This contract, and any changes to it, will be interpreted on the basis that both parties contributed equally to the drafting of each of its parts. 

 

			
	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH:
		
	Signed:	 	/s/ [Illegible]
	Printed Name:	 	[Illegible]
	Title:	 	Vice Pres
		
	Date:	 	6-4-07
	
	COMPANY:
		
	Signed:	 	/s/ Christian Homsy
	Printed Name:	 	Christian Homsy
	Title:	 	CEO
		
	Date:	 	6-4-07

  
 -Page 10 of
10- 

 MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 

FIRST AMENDED TECHNOLOGY LICENSE CONTRACT 
 Article 1.00 - Preliminary Provisions. 
  

	1.01	EFFECTIVE DATE. The effective date of this contract is July 1, 2008. 

 

	1.02	PARTIES. There are two parties to this contract (together called “the Parties” or individually “a Party”). They are:

  

	(a)	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH, a Minnesota charitable corporation, located at 200 First Street SW, Rochester, Minnesota 55905-0001 (called
“MAYO” in this contract), and 

  

	(b)	 Cardio3 BioSciences S.A., a Belgian company, located at Boulevard de France 9, 1420 Braine l’Alleud, Belgium (called the “COMPANY” in this contract). 

1.03 PURPOSE OF CONTRACT. This is the first amended version of the Technology License Contract between the parties originally signed
June 4, 2007. Certain inventions have been made in connection with MAYO’s research, patient care and education programs. By assignment of the inventions from the inventors, MAYO owns certain patent-rights, and know-how. MAYO intends to
grant licenses to use its patent rights, and know-how for the development of products, processes and methods for public use and benefit. The COMPANY intends to develop marketable products, processes and methods for public use and benefit within the
Territory described in this contract, by using the Licensed Invention and Licensed Know-How. Both parties acknowledge that MAYO has carefully selected the COMPANY because of the COMPANY’s best suited characteristics which make the COMPANY
especially suitable as a licensee of the invention. The COMPANY enters this licensing contract with MAYO for use of the Licensed Invention, patent rights, and KNOW-HOW on an exclusive basis, subject only: (a) to MAYO’s right to make and
use the Licensed Invention and Know-How on a royalty-free basis within its Affiliates’ own programs; and (b) to the rights, if any, of the United States government. 
 Article 2.00 - Definitions. 
 LICENSED INVENTION means Cardiogenic Cocktail for
Production of Cardiac Cells (MAYO reference number MMV# 2004-182) methods for the preparation of the cardiogenic cocktail, methods of the preparation of the cardiac cells using the cardiogenic cocktail and cardiac cells obtained in such methods, and
use of the cardiogenic cocktail and/or cardiac cells in methods for treating cardiovascular tissue. If not patented, then the Licensed Invention is MAYO’s trade secret. This definition also includes licensed patent rights under pending PCT
Patent Application Serial No. WO2006/05127, filed July 29, 2005; US20080019944, filed February 13, 2007 and Patent Application titled, “METHODS AND MATERIALS FOR USING CELLS TO TREAT HEART TISSUE” filed on May 27, 2008, and
any divisions, continuations, and continuations-in-part based thereon, and any patents which may issue therefrom, and any reissues or extensions thereof. 

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 2.01 AFFILIATE for Mayo shall mean, any corporation or other entity within the same
“controlled group of corporations” as Mayo or its parent, Mayo Clinic. For purposes of this definition, the term “controlled group of corporations” will have the same definition as section 1563 of the Internal Revenue Code as of
November 10, 1998, but will include corporations or other entities which if not a stock corporation, more than 50% of the board of directors or other governing body of such corporation or other entity is controlled by a corporation within the
controlled group of corporations of MAYO or Mayo Clinic. Mayo’s Affiliates include, but are not limited to: Mayo Clinic; Mayo Collaborative Services, Inc.; Rochester Methodist Hospital; Saint Marys Hospital; Mayo Clinic Rochester; Mayo Clinic
Jacksonville; St. Luke’s Hospital Association; Mayo Clinic Arizona; and its Mayo Health System entities. 
 2.02
FIELD OF USE means treatment of embryonic and autologous mesenchymal stem cells to guide development into
cardiomyocytes for the treatment of myocardial infarction, ischemic heart disease, ischemic and non-ischemic cardiomyopathy. 
 2.04
QUARTER begins on the date in Section 1.01 of this contract, and thereafter begins on the first day of each January, April, July, and October during the term of this contract. 
 2.05 YEAR begins on the date in Section 1.01 of this contract, and thereafter begins on the first day of each January during the term of this contract. 

2.06 LICENSED KNOW-HOW means trade secrets including technical information, whether or not patentable, including but not limited to engineering,
scientific, and practical information and formulas; information about qualities, uses, and sales methods and procedures; information about materials and sources; blueprints, drawings, specifications, and other relevant writings used in the design,
manufacture, and sale of products, processes, and methods in connection with the Licensed Invention. 
 2.07 MAYO INFORMATION means all
information embodied in the Licensed Invention, and Licensed Know-How, or, expressly marked, labeled, referenced in writing, which is disclosed to the COMPANY by MAYO, relating in any way to MAYO’s markets, customers, patents, inventions
products, procedures, designs, plans, organization, employees, or business in general, but not including: 
  

	(a)	information which, before disclosure becomes part of the public domain through no action or fault of the COMPANY; or 

 

	(b)	information which the COMPANY can show was in its possession before disclosure by MAYO to the COMPANY and was not acquired, directly or indirectly, from MAYO; or

  

	(c)	information which was received by the COMPANY from a third party having a legal right to transmit such information. 

2.08 TERMINATION of this contract means the ending, expiration, rescission, or any other discontinuation of this contract for any reason
whatsoever. 
  

	2.09	TERRITORY means the world. 

  
 Page 2 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 Article 3.0 - Grant of Rights. 

3.01 GRANT. Subject only to the exceptions described in Section 1.03 of this contract, MAYO grants to the COMPANY an exclusive license to
make, have made, use, modify, enhance, promote, market and/or sell the Licensed Invention whether or not patented, and a non-exclusive right to use the Licensed Know-How, in the Territory within the Field of Use, according to the terms of this
contract. The Licensed Invention and Know-How, if not patented, are trade secrets of MAYO. 
 3.02 PURCHASE AT COST. MAYO may, at its
sole option, purchase the Licensed Invention in any quantity at cost from the COMPANY, and use the Licensed Know-How without cost to MAYO, exclusively within MAYO’s and its Affiliates’ own programs provided such programs are only for
internal (research or clinical) use and do not include any allocation of right to any third party neither any sale of marketing of products derrivated from the Licensed Inventior. No Royalty will be due to MAYO for these sales to MAYO. 

3.03 DISCLOSURE OF KNOW-HOW. Company acknowledges that MAYO has successfully transferred the know-how to the COMPANY. MAYO, however, owns the
materials in which the Licensed Know-How is embodied, including, but not limited to, prototypes, lab notebooks and copies of lab notebooks, blueprints, and plans. The COMPANY shall have the right to confer with the inventors (so long as they are
employees of MAYO or its Affiliates) for a reasonable period and at such times that are mutually convenient. 
 3.04 CONFIDENTIAL
INFORMATION means any and all information, data, results, Inventions, trade secrets, techniques, material, or compositions of matter of any type or kind, including without imitation all know-how and all other scientific, pre-clinical, clinical,
regulatory, manufacturing, marketing, personnel, financial, legal and commercial information or data, whether communicated in writing, orally or by any other method, that a Party treats or identifies as confidential and, in each case, is disclosed
by one Party to the other Party with respect to such disclosing Party’s rights or obligations under this contract. 
  

	3.05.01	Disclosure Obligation 

  

	(a)	Confidential Information. All Confidential Information shall be maintained in confidence by the receiving Party and shall not be disclosed to any non-Party (N.B.
subcontractor free lance associates are not covered - see D) or used for any purpose except to exercise its rights and perform its obligations under this contract without the prior written consent of the disclosing Party, except to the extent that
the receiving Party can demonstrate by competent written evidence that such Confidential Information: 

 (i) is
known by the receiving Party at the time of its receipt and, not through a prior disclosure by the disclosing Party, as documented by the receiving Party’s business records; 

(ii) is in the public domain other than as a result of any breach of this Agreement by the rcceiving Party; 

  
 Page 3 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 (iii) is subsequently disclosed to the receiving Party on a non-confidential basis by a
third party who may lawfully do so; or 
 (iv) is independently discovered or developed by the receiving Party without the use of
Confidential Information provided by the disclosing Party, as documented by the receiving Party’s records. 
  

	(b)	Return of Confidential Information Upon Expiration or Termination of contract. Within thirty (30) days after any expiration or termination of this contract,
each Party shall destroy (and certify to the other Party such destruction) or return (as requested by the other Party) all Confidential Information provided by the other Party except as otherwise set forth in this contract, and except that each
Party may retain a single copy of the Confidential Information in its confidential legal files for the sole purpose of ascertaining its ongoing rights and responsibilities regarding the Confidential Information. 

3.05.02 Permitted Disclosures 
  

	(c)	Permitted Disclosure. Each Party may disclose Confidential Information provided by the other Party to the extent such disclosure is reasonably necessary in the
following instances: 

  

	 	(i)	disclosure to governmental or other regulatory agencies in order to obtain patents, or to gain or maintain approval to conduct clinical trials or to market Licensed
Invention (in each case to the extent permitted by this contract), but such disclosure may be only to the extent reasonably necessary to obtain patents or authorizations; 

 

	 	(ii)	complying with applicable court orders or governmental regulations, including without limitation rules or regulations of the Securities and Exchange Commission, or by
rules of the National Association of Securities Dealers, any securities exchange or NASDAQ; provided, however, that the receiving Party shall first have given notice to the other Party hereto in order to allow such Party the opportunity to seek
confidential treatment of the Confidential Information; 

  

	 	(iii)	disclosure to consultants, agents or other third parties solely to the extent required to accomplish the purposes of this contract or in connection with due diligence
or similar investigations by such third parties, and disclosure to potential third party investors in confidential financing documents, in each case on the condition that such third parties agree to be bound by confidentiality and non-use
obligations at least equivalent in scope to those contained in this contract or for the purposes of such financing; provided the term of confidentiality for such third parties shall expire no less than three (3) years after the expiry or
earlier termination of this contract. 

  
 Page 4 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

	(d)	Written Agreements. Each Party shall have in effect a policy requiring or obtaining written agreements from each of its employees, consultants and contractors
who perform work on the Sponsored Research Program, which agreements shall obligate such persons to similar obligations of confidentiality and to assign to such Party all know-how, information and Inventions conceived, made or reduced to practice by
such persons during the course of performing the Sponsored Research Program. Each Party will notify the other Party promptly upon discovery of any unauthorized use or disclosure of the Confidential Information of the other Party.

  

	(c)	Required Disclosure. If a Party is required by judicial or administrative process to disclose Confidential Information that is subject to the non-disclosure
provisions of Section 3.04.1, such Party shall promptly inform the other Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Each Party shall provide
reasonable cooperation to the other Party in any such process. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise subject to the confidentiality and non-use provisions of this article 3.04, and
the Party disclosing Confidential Information pursuant to law or court order shall take all reasonable steps necessary, including without limitation obtaining an order of confidentiality, to ensure the continued confidential treatment of such
Confidential Information. 

 3.05.03 Publication. If a Party, its employees or consultants wishes to make a written
publication or oral presentation related to a Licensed Invention, that Party shall deliver to the non-publishing Party a copy of the proposed written publication or an outline of an oral disclosure at least thirty (30) days prior to submission
for publication or presentation. The non-publishing Party shall have the right to review and propose modifications to the publication or presentation for patent reasons, trade secret reasons or business reasons or (b) to request a reasonable
delay in publication or presentation in order to protect patentable information. If the non-publishing Party requests modifications to the publication or presentation, the Party wishing to make such written publication or oral presentation shall
edit such publication or presentation to prevent disclosure or trade secret or proprietary business information of the non-publishing Party prior to submission of the publication or presentation, and/or delay such publication or presentation.

 3.05.04 Publicity/Use of Names 
  

	(f)	General. Either Party shall be free to disclose, without the other Party’s prior written consent, the existence of this contract, the identity of the other
Party and those terms of the contract which have already been publicly disclosed in accordance herewith. 

  

	(g)	Trademarks. Except as set forth in Section 3.04.4(a), or as expressly permitted by this contract, neither Party shall use the name, trademark, trade name or
logo of the other Party or its employees, including in any publicity, news release or disclosure relating to this contract or its subject matter, without the prior express written permission of the other Party. 

  
 Page 5 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

	(h)	Protection of Interests. The Parties will use commercially reasonable efforts to ensure that the content of any oral statement or written disclosure or
publication will comply with applicable laws and regulations and will not adversely affect the Parties’ commercial interests. 

 Article 4.00 - Consideration and Royalties. 
 4.01 CONSIDERATION. The license
Grant under this contract will be remunerated with an initial royalty, which is non-refundable and amounts to € 9,500,000.00. No other royalties will be due. 
 4.02 TAXES. Unless in case of purchase at cost (see section 3.03 here above) the COMPANY is responsible for all taxes (other than net income taxes), duties, import deposits, assessments, and other
governmental charges, however designated, which are now or hereafter will be imposed by any authority in or for the Territory, (a) by reason of the performance by MAYO of its obligations under this contract, or the payment of any amounts by the
COMPANY to MAYO under this contract; (b) based on the Licensed Invention or use of the Licensed Invention; or (c) which relate to the import of the Licensed Invention into the Territory. 

4.03 NO DEDUCTIONS. All payments to be made by the COMPANY to MAYO under this contract represent net amounts MAYO is entitled to receive, and
shall not be subject to any deductions or offsets for any reason whatsoever. If such payments become subject to taxes, duties, assessments, or fees of any kind levied in the Territory, such payments from the COMPANY shall be increased to the extent
that MAYO actually receives the net amounts due under this contract 
 4.04 U.S. CURRENCY. All payments to MAYO under this contract shall
be made by draft drawn on a United States bank, and payable in United States dollars. 
 Article 5.00 - Research

 5.01 RESEARCH FUNDING. Beginning in 2008, and for a total of three years COMPANY will contribute to research funding at MAYO in
the amount of $742,500.00 per year. The research projects hereto related will be documented in advance with a project plan and budget which will be proposed by MAYO mutually agreed after discussion out of good faith among the parties. These projects
plans shall include specific aims and deliverables to be reasonably acceptable to the Company. In this context, payments will be made in four equal quarterly installments of $ 185,625.00 payable at the beginning of each relevant quarter. Any
improvements developed in the course of work under any of these projects plans will fall under the license Grant in this contract. MAYO will report any research findings under this Section 5.01 to the COMPANY in writing on a quarterly basis
(hereinafter “the Sponsored Research”). 
 5.02 COMPANY DIRECTED RESEARCH In addition to the research under Section 5.01,
MAYO and COMPANY will develop a budget, timeline and list of specific deliverables for any research that the COMPANY and MAYO desire to perform. 

  
 Page 6 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 5.03 PURCHASE OF EQUIPMENT. COMPANY will pay MAYO $337,000.00 to be used to purchase equipment to
be used for the Sponsored Research described in Sections 5.01 and 5.02. This equipment may be used for other research at MAYO but preference will be given to any project funded by COMPANY. This payment is due no later than September 30, 2008.

 Article 6.00 - Warranties and Indemnification. 
 6.01 Mayo represents and warrants to COMPANY that to the best of Mayo’s internal patent counsel’s knowledge, no third party has sent written notice to Mayo that practice of the Licensed
Invention infringes on any third party’s intellectual property rights. 
 6.02 USE OF NAME AND LOGO. The
COMPANY shall not use publicly for publicity, promotion, or otherwise, any logo, name, trade name, service mark, or trademark of MAYO or its Affiliates, including, but not limited to, the terms “MAYO®”, “Mayo Clinic®,” or any simulation, abbreviation, or adaptation of the same, or the name of any MAYO employee or agent, without MAYO’s prior, written, express consent.
MAYO may withhold such consent and will process such requests within 5 business days. 
 6.03 MAYO PATENTS. Except as expressly provided
in this contract, nothing shall be construed 
  

	(a)	a warranty or representation by MAYO as to the validity or scope of any patents contained in the Licensed Invention; 

 

	(b)	an obligation to bring or to prosecute actions against third parties for infringement of patent 

 

	(c)	conferring by implication, estoppel, or otherwise any patents of MAYO. 

 6.04 WARRANTIES. MAYO HAS NOT MADE AND PRESENTLY MAKES NO PROMISES, GUARANTEES, REPRESENTATIONS OR WARRANTIES OF ANY NATURE, DIRECTLY OR INDIRECTLY, EXPRESS OR IMPLIED, REGARDING THE
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, SUITABILITY, DURABILITY, CONDITION, QUALITY, OR ANY OTHER CHARACTERISTIC OF THE LICENSED INVENTION. THE COMPANY TAKES THE LICENSED INVENTION “AS IS,” “WITH ALL EVENTUAL TECHNICAL
FAULTS,” AND “WITH ALL EVENTUAL 
 DEFECTS.” 
 6.05 INDEMNIFICATION. The COMPANY will defend, indemnify, and hold harmless MAYO and MAYO’s Affiliates from any and all third party claims, actions, demands, judgments, losses, costs,
expenses, damages and liabilities (including but not limited to reasonable attorneys fees and other expenses of litigation), regardless of the legal theory asserted, arising out of or connected with: 

 

	(a)	use by the COMPANY of Patent Rights or information furnished or licensed under this Agreement; 

  
 Page 7 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

	(b)	design, manufacture, distribution, use, sale, or other disposition of Products, including Licensed Products, by the COMPANY or its transferees; and

  

	(c)	any obligation of COMPANY hereunder. 

 As used
in Sections 6.04 and 6.05, MAYO and its Affiliates include the trustees, officers, agents, and employees of MAYO and its Affiliates. The parties agree that the indemnity stated in this Section 6.04 should be construed and applied in favor of
indemnification. COMPANY will, during the Term, carry insurance at a level commensurate with their obligation to indemnify MAYO In any case, prior to any use in humans, COMPANY will carry occurrence-base liability insurance, including products
liability and contractual liability, in an amount and for a time period sufficient to cover the liability assumed by COMPANY hereunder, such amount being at least one million U.S. dollars ($1,000,000.00). Notwithstanding the foregoing, COMPANY shall
not, without MAYO’s prior written consent, settle or compromise any Claim in a manner that would require MAYO to admit liability or incur financial obligation. MAYO may be represented by counsel of its own choosing, at its own expense.

 6.06 ADDITIONAL WAIVERS. THE COMPANY AGREES THAT MAYO SHALL NOT BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY DELAY IN FURNISHING
PRODUCTS OR SERVICES, OR ANY OTHER PERFORMANCE UNDER THIS CONTRACT, UNLESS RESULTING FROM MAYO’S NEGLIGENCE OR WILLFULL AND WANTON MISCONDUCT. 
 IN NO EVENT SHALL PARTIES’ LIABILITY OF ANY KIND INCLUDE ANY SPECIAL, INDIRECT, INCIDENTAL, OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF THE BREACHING PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH
DAMAGES. IN NO CASE SHALL PARTIES’ LIABILITY FOR DAMAGES OF ANY TYPE EXCEED THE DOUBLE OF TOTAL ROYALTIES WHICH HAVE ACTUALLY BEEN PAID TO MAYO BY THE COMPANY AS OF THE DATE OF FILING OF THE ACTION AGAINST MAYO WHICH RESULTS IN THE SETTLEMENT
OR AWARD OF DAMAGES. 
 Article 7.00 - Term and Termination. 
 7.01 TERM, The term of this contract is for the longer of ten (10) years, or for the life of the last of any patents that may be related to the Licensed Invention. 

 

	7.02	TERMINATION. 

 a)
This Agreement may be terminated only to the extent provided in this Agreement or by mutual written agreement between the Parties. Early termination of this Agreement by mutual written agreement as provided for in Section 7.02 (a) shall not
relieve the Parties of any obligation accruing prior to such termination. 
 b) COMPANY may terminate the Agreement on at least
90 days prior written notice to MAYO if in COMPANY’s reasonable opinion the licensed Invention is no longer scientifically, regulatory, clinically or economically potentially valuable to the Company including manufacturing cost and cost -
benefit ratio consideration. 

  
 Page 8 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 c) If the COMPANY defaults in the payment of any fees, or payment, or in the making of
any report; or makes a false report MAYO may, at its sole option, terminate this contract upon written notice to the COMPANY. Termination being effective upon one hundred and twenty (120) days after mailing or personal delivery unless such
default or other breach is first cured. 
 d) MAYO may terminate this license at any time after January 2011 if MAYO, has
reasonable evidence that the COMPANY does not intend to develop the Licensed Invention commercially. MAYO and the COMPANY will first try to resolve the disagreements in good faith. Should the disagreements remain, MAYO and the COMPANY agree to
binding arbitration as to the validity of the evidence 
 7.03 CHALLENGE BY OR INSOLVENCY OF COMPANY. MAYO may terminate this
contract immediately upon written notice to the COMPANY if the COMPANY ceases conducting business in the normal course, becomes insolvent or bankrupt, makes a general assignment for the benefit of creditors, admits in writing its inability to pay
its debts as they are due, permits the appointment of a receiver for its business or assets, or avails itself of or becomes subject to any proceeding under any statute of any governing authority relating to insolvency or the protection of rights of
creditors. 
 7.04 SURVIVAL. The following obligations survive the Termination of this contract: 

 

	a)	the COMPANY’s obligation to supply reports covering the time period up to the date of Termination; 

 

	b)	MAYO’s obligation pursuant to Section 5 to supply reports covering the time period up to the date of Termination; 

 

	c)	MAYO’s right to receive payments, fees, and royalties (including minimum royalties) accrued or accruable from payment at the time of any Termination;

  

	d)	the COMPANY’s obligation to maintain records, and MAYO’s right to have those records inspected; 

 

	e)	any cause of action or claim of MAYO, accrued or to accrue, because of any action or omission by the COMPANY; 

 

	f)	the COMPANY’s obligations stated in Sections 3.04, 6.02 and 6.05 of this contract; and 

 

	g)	unless if terminated pursuant to section 7.02, the COMPANY’s obligation to return all materials given to it by MAYO, including inventory. 

Article 8.00 - Best Efforts. 
 8.01 REPRESENTATIONS OF THE COMPANY. The COMPANY has represented to MAYO, to induce MAYO to enter into this contract, that the COMPANY is experienced in the development, production, quality
control, service, manufacture, marketing, and sales of products similar to the Licensed Invention, and that it will commit itself to a thorough, vigorous, and diligent program of marketing the Licensed Invention. COMPANY also represents to MAYO that
all product sold in the United States will be manufactured substantially in the United States. 

  
 Page 9 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 8.02 COMPANY EFFORTS. If at any time during the term of this contract, the COMPANY is not
exercising, or is presently unable to exercise, its best efforts in the development, production, quality control, service, manufacture, marketing, or sales of the Licensed Invention, then MAYO may terminate the exclusivity of this contract if
COMPANY does not cure within 120 days of written notice to the COMPANY. The criteria MAYO may use in reaching such a conclusion include, but are not limited to, the loss for any reason of key personnel from the COMPANY, and the present or projected
financial status of the COMPANY. 
 8.03 MAYO EFFORTS. If at any time during the term of this contract, MAYO is clearly not exercising,
or is presently unable to exercise, reasonable efforts in the execution of this contract, COMPANY will promptly notify MAYO of any specific actions or inactions that indicate such lack of effort. If MAYO does not reasonably cure within 120 days,
COMPANY will no longer be obliged to pay any outstanding research funding upon written notice to MAYO. 
 Article 9.00 -
Patents 
 9.01 PATENT NUMBERS. The COMPANY shall mark all Licensed Invention units sold in the United States with any applicable
United States patent numbers, and all Licensed Invention units sold in countries other than the United States with any applicable patent numbers of the country of sale. All Licensed Invention units shipped to or sold in other countries in the
Territory shall be marked in such a manner as to conform with the patent laws and other laws of the country of manufacture or sale. 
 9.02
INFRINGEMENT BY THIRD PARTY. Notwithstanding anything else in this contract, if at any time a third party shall infringe any unexpired licensed patent right licensed in this contract, and if such infringement shall come to the attention of
either MAYO or the COMPANY, that party shall promptly give notice in writing to the other party of the existence of such infringement, and the parties to this contract shall, upon mutual agreement, decide on an appropriate course of action to take
against the infringer in view of all of the circumstances then existing. MAYO shall not unreasonably withhold such agreement. 
 9.03
PATENTS. The COMPANY, at its own discretion, shall pursue patent coverage and maintain patents for the Licensed Invention at its own expense. Any patents resulting from the Licensed Invention or based upon the Licensed Invention shall be owned
and applied for on behalf of MAYO if invented by MAYO, assigned to COMPANY if invented by COMPANY and jointly assigned of jointly invented. When the COMPANY decides not to seek patent protection for (certain parts) of the Licensed Invention, it
shall offer MAYO the right to seek protection for such parts of the Licensed Invention, such patents to be owned solely by MAYO and COMPANY will have no rights. 
 MAYO shall do, execute and perform and shall procure to be done, executed and performed all such further acts, deeds, documents and things as COMPANY may reasonably require from time to time effectively
to pursue the patents. 

  
 Page 10 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 Article 10.00 - General Provision 

10.01 ASSIGNMENT AND SUBCONTRACT. The COMPANY and MAYO are strictly prohibited from assigning or subcontracting any of their obligations or rights
under this contract without the other party’s prior, express, written consent, which consent may not be unreasonably withheld. 
 10.02
WAIVER. No part of this contract may be waived except by the further written agreement of the parties. Forbearance in any form from demanding the performance of a duty owed under this contract is not a waiver of that duty. Until complete
performance of a duty owed under this contract is accomplished, the party to which that duty is owed may invoke any remedy under this contract or under law, despite its past forbearance in demanding performance of that duty. 

10.03 GOVERNING LAW AND JURISDICTION. This contract is made and performed in Minnesota. It is governed by Minnesota law, but specifically
not including Article 2 of the Uniform Commercial Code as enacted in Minnesota. This is not a contract for the sale of goods. In addition, no Minnesota conflicts-of-law or choice-of-laws provisions apply to this contract, it supersedes the
application of Minnesota law. [The exclusive fora for actions between the parties in connection with this contract are the State District Court sitting in Olmsted County, Minnesota, or the United States Court for the District of Minnesota.]

 10.04 HEADINGS. The headings of articles and sections used in this document are for convenience of reference only, and arc not
a part of this contract. 
 10.05 NOTICES. Any notice required to be given under this contract is properly provided if in writing
and either personally delivered, or sent by express or certified mail, postage prepaid, to the parties at the following addresses, unless other addresses are provided consistent with this Section 10.5: 

Mayo Foundation for Medical Education and Research 
 200 First Street SW 
 Rochester, Minnesota 55905-0001 

Attn: Office of Intellectual Property, Mayo Clinic 
 Cardio3
BioSciences 
 Boulevard de France 9 

1420 Braine l’Alleud 
 Unless otherwise
expressly specified in this contract in this contract, notices sent by mail are considered effective upon the earlier of: the fifth (5th) day after dispatch (or the tenth (10th) day after dispatch if dispatched by air mail other than in
the United States) or the day of actual receipt. Notices personally delivered are considered effective upon the date of delivery. It is the responsibility of the party giving notice to obtain a receipt for delivery of the notice, if that party
considers such a receipt advisable. 

  
 Page 11 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

 10.06 LIMITED OF RIGHTS CREATED. This contract is intended only to benefit the two parties to it.
They have no intention to create any interests for any other party. Specifically, no interests are intended to be created for any customer, patient, research subjects, or other persons (or their relatives, heirs, dependents, or personal
representatives) by or upon whom the Licensed Invention may be used. 
 10.07 INDEPENDENT CONTRACTORS. In the performance of their
respective duties under this contract, the parties are independent contractors of each other. Neither is the agent, employee, or servant of the other. Each is responsible only for its own conduct. 

10.08 ENTIRE CONTRACT. This document states the entire contract between the parties about its subject matter. All past and contemporaneous
discussions, agreements, proposals, promises, warranties, representations, guarantees, correspondence, and understandings, whether oral or written, formal or informal, are entirely superseded by this contract. 

10.09 UNENFORCEABLE PROVISION. The unenforceability of any part of this contract will not affect any other part. This contract will be construed
as if the unenforceable parts had been omitted. 
 10.10 CHANGES TO CONTRACT. No part of this contract, including this
Section 10.10, may be changed except in writing, through another document signed by both parties. 
 10.11 CONSTRUCTION. Both
parties agree to all of the terms of this contract. Both parties execute this contract only after reviewing it thoroughly. This contract, and any changes to it, will be interpreted on the basis that both parties contributed equally to the drafting
of each of its parts. 
 (Remainder of this page intentionally left blank) 

  
 Page 12 of 13

 Mayo Clinic/Cardio3 BioSciences S.A. 
 July 3, 2008 
  

			
	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH:
		
	Signed:	 	 /s/ Steven P. VanNurden

	Printed Name:	 	Steven P. VanNurden
	Title:	 	Assistant Treasurer
		
	Date:	 	July 3, 2008
	
	COMPANY:
		
	Signed:	 	 /s/ Michel Lussier

	Printed Name:	 	Michel Lussier
	Title:	 	Chairman
		
	Date:	 	July 4, 2008

  
 Page 13 of 13

 Execution copy 

 

 Amendment Number 2 

To the Technology License Contract between 
 Mayo Foundation for Medical Education and Research 
 And 

Cardio3 BioSciences SA 

Whereas the parties signed a Technology License Agreement effective June 4, 2007. 
 Whereas the parties signed a first amendment to that Technology License Contract on July 1, 2008 (the Technology License Contract, as amended, being referred to as the “License
Agreement”). 
 Whereas the parties wish to re-consolidate and enhance the strategic alignment between Mayo and the Company and to
reinforce the global relationship between Mayo and the Company to their mutual benefit. 
 Whereas the parties wish to confirm their global
strategic relationship in the field of regenerative or protective therapies for cardiovascular applications; whereas the parties also wish to create certainty regarding the Company’s protein (non-cellular) and allogeneic programs. 

Whereas the Parties wish to expand and amend the terms of the License Agreement as set forth below in this Second Amendment of the License Agreement (the
“Second Amendment”) dated, and effective as of, 18 October 2010. 
 1. Delete the fifth and sixth sentences of
Section 1.03 
 2. Article 2.00 (“Definitions”), paragraph “Licensed Inventions” shall be replaced with: 

2.00 LICENSED INVENTIONS means “Cardiogenic Cocktail for the production of Cardiac Cells” (Mayo Reference number
MMV#2004-182) and “Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure” (Mayo Reference number MMV#2007-121). If not patented, then the Licensed Inventions are MAYO’s trade secret. To Mayo’s knowledge, the two
inventions explicitly listed encompass Mayo’s inventions and intellectual property on guided cardiopoiesis as of the date of execution of the Second Amendment. Licensed Inventions also includes the following patent applications, and all
divisionals, continuations and continuations in part based thereon, and any patents which may issue therefrom, and any reissues or extensions thereof (together, the “Licensed Patents”) and know-how. 

Licensed Inventions includes those patents listed below: 
 2007-121, Stem Cell Based Therapy for Non-ischemic Cardiomyopathic Heart Failure, 

  
 1 

 Execution copy 

 

 2004-182 Derivation of a Cardiopoetic Cellular Phenotype from a Stem Cell Source. 

And the related Patents and Patent Applications; 

06/592,871 Stem Cells and treatment of Vascular Tissue 
 06/680,775 Treating Cardiovascular Tissue 
 06/832,845 Methods and Materials for providing Cardiac
Cells 
 PCT/US2005/026800 Treating Cardiovascular Tissue 
 PCT/US2008/064895 Methods and Materials for using Cells to treat Heart Tissue 
 PCT/US2009/044714
Compositions and Methods for Using Cells to treat Heart Tissue 
 PCT/US2009/044751 Methods for determining the Cardio Generative Potential of
Mammalian Cells 
 3. Paragraph 2.02 is replaced with the following; 
 2.02 FIELD OF USE means cardiovascular regeneration or protection. 
 4. Delete definition
“Mayo Information”. Delete Section 3.05.02(c) (“Required Disclosure”). 
 5. Add Paragraph 2.10 

2.10 SUBLICENSE. Company has the right to sublicense, without Mayo consent, but under the following terms and conditions. Any sublicense by
Company shall be to a Sublicensee that agrees in writing to be bound by (at least) substantially the same terms and conditions as Company herein, excluding the financial terms and conditions, or such sublicense shall be null and void. Sublicenses
granted hereunder shall not be transferable, including by further sublicensing, delegatable or assignable (except among affiliates of the sublicensees or in the context of distribution agreements or the intervention of commercial sales
organizations) without the prior written approval of Mayo, which shall not unreasonably be withheld, delayed or conditioned. Company will provide Mayo with a copy of each sublicense agreement promptly after execution. Company is responsible for the
performance of all sublicensees as if such performance were carried out by Company itself, including the payment of any royalties or other payments provided for hereunder triggered by sublicensee, regardless of whether the terms of any sublicense
require that sublicensee pay such amounts (such as in a fully paid-up license), or that such amounts be paid by the sublicensee directly to Mayo. Each sublicense agreement shall name Mayo as a third party beneficiary. Unless Mayo has provided
written consent, the rights of the sublicensee shall terminate when Company’s rights terminate. However, Mayo shall not withhold its consent unreasonably, in cases where the relevant sublicensees have up to that time substantially complied with
their obligations under the sublicense agreement. 
 6. Add Paragraph 3.06 
 3.6 “NET COMMERCIAL SALES”: the amount invoiced by Company or Sublicensee for the commercial transfer of a Licensed Product to a non-sublicensee or non-affiliated third party less the sum
of the following documented items: (a) sales, excise or use taxes or other taxes, tariffs, customs duties, excise or other duties or governmental charges shown on the face of the invoice; (b) repayments or credits for defective, rejected,

  
 2 

 Execution copy 

 

 
recalled or returned Licensed Products actually given; (c) trade and discount allowances, price reductions, rebates and adjustments given (including if imposed by governmental authorities,
or if granted to drug wholesalers or their customers in cases where there are not direct shipments to such customers); (d) transportation, importation, exportation, shipping, insurance and other handling expenses chargeable to the
royalty-bearing sale of the Licensed Product; and (e) accounts receivable that are not collected within 4 months from their due date. Net Commercial Sales will not include any reimbursement received or revenue in respect of the use of a
Licensed Product as part of a clinical trial or otherwise prior to the receipt of marketing authorization. Net Commercial Sales on Licensed Products transferred as part of a non-cash exchange shall be calculated at the then-current customary
commercial sales price invoiced to third parties or fair market value if there are no current invoices to third parties. 
 7. Add a second
clause to Paragraph 4.01 
 “The entry into the Second Amendment (including the additional license grant) will be remunerated with an
upfront fee amounting to $3,193,125.” 
 8. Amend Section 4.03 as follows: add “(other than net income taxes)” after
“taxes”. 
 9. Add Paragraph 4.05 
 4.05 EARNED ROYALTIES. Company will make nonrefundable and noncreditable earned royalty payments to Mayo of 2% of Net Commercial Sales which absent the amended License Agreement would infringe a
valid claim of a Licensed Patent (the “Licensed Product”) (“Earned Royalties”). Earned Royalties will be due, on a Licensed Product-by-Licensed Product basis, during a royalty period beginning on the date of
the first commercial sale of the relevant Licensed Product and extending until the earlier of (i) termination of this agreement; (ii) the 15 year anniversary of the first commercial sale of such Licensed Product; (iii) the date on which
such Licensed product is no longer covered by a valid claim of a Licensed Patent in the territories in which it is sold Upon expiry of the royalty period, the license becomes perpetual and fully paid up for the relevant Licensed Product, with the
right to sublicense pursuant to Section 2.10 of this amendment. Royalties paid under this section 4.05 may be reduced by the amounts paid to a third party if COMPANY obtains a license to a third party right that is necessary to
develop/commercialize a Licensed Product, without, however, the effective royalty rate paid to Mayo falling below 1.5%. The Earned Royalties are payable as described in Section 4.06. Licensed Products sold or transferred to Mayo or its
Affiliates are not considered transfers for purposes of determining Net Commercial Sales or for calculating Earned Royalties. No Earned Royalties are due to Mayo on transfers to Mayo or Mayo Affiliates. 

10. Add Paragraph 4.06 
 4.06 REPORTS AND
PAYMENT. Company will deliver to Mayo on or before the following dates: 1 March, 1 June, 1 September, and 1 December, payment of Earned Royalties (paid in US Dollars, converted from the currency in which the sales were made
at the rate published in the Wall Street Journal on the business day prior to the date that the payment is made) along with a written report setting forth a full accounting showing 

  
 3 

 Execution copy 

 

 
how any amounts due to Mayo for the preceding calendar quarter have been calculated as provided in this Agreement, including an accounting of total Net Commercial Sales with a reporting of any
applicable foreign exchange rates, deductions, allowances, and charges, and any payments received from Sublicensees. If no qualified Licensed Product transfers have occurred and no Earned Royalties are due to Mayo, Company will submit a report so
stating. Each such report will be accompanied by the payment of all amounts due for such calendar quarter. Items to be deducted as per the definition of Net Commercial Sales, can be deducted (or should be repaid) in subsequent quarters. 

11. Change Section 5.01 to: 
 5.01
RESEARCH FUNDING. In 2010, COMPANY will be entitled to $185,625 worth in directed research by Mayo without additional consideration, other than the acceptance of the royalty provisions under this Second Amendment. In 2011, COMPANY will be
entitled to $750,000 worth in directed research by Mayo without additional consideration, other than the acceptance of the royalty provisions under this Second Amendment. MAYO and COMPANY will work together and negotiate in good faith to find
projects of mutual interest in the Field of Use and to develop a specific research agreement spelling out, amongst other things, a budget, deliverables and a timeline. Any results of this research will automatically fall under the license grant in
the Technology License Contract and constitute Licensed Inventions (even if not covered by “Licensed Inventions” as initially defined in the Second Amendment). Any amounts not actually spent in any given calendar year will be transferred
to the following calendar year and so on. Mayo will report any research findings to the Company in writing on a quarterly basis. Also, COMPANY will be entitled to the conduct, by Mayo, without additional consideration, other than the acceptance of
the royalty provisions under this Second Amendment, of a dose finding study worth $250,000. 
 12. Add a new Section 5.04 

5.04 CONTRIBUTION INTO THE CAPITAL OF COMPANY. Mayo hereby agrees to convert the following outstanding invoices in capital of the Company at the
occasion of the upcoming Series C funding of the Company for a total amount of $4,181,250, in consideration for Class B Shares at a price of EUR 44.20 per share: (i) unpaid Research Funding 2009 under the First Amended License Agreement,
invoice reference 2004182101210 ($186,250); (ii) unpaid Research Funding 2010 (i.e., the portion of $742,500 already consumed for 2010 on the date of this Second Amendment, more specifically $556,875) under the First Amended Technology License
Contract, invoice reference 2004182101210; (iii) unpaid delivery of 70 liters Platelet Lysate (under the Material Transfer Agreement dated 1 July 2010), invoice reference 2004182101210 ($245,000); and (iv) the upfront fee under the
second paragraph of section 4.01 of the Second Amendment, invoice reference 2004182101210 ($3,193,125). For the capital increase, the USD/EUR conversion rate on 30 September 2010 will be applied. The contribution in kind is subject to approval
by the Company’s corporate bodies. 

  
 4 

 Execution copy 

 

	13.	Add Section 5.01.01 

 5.01.01 CONTINGENT
RESEARCH FUNDING. COMPANY will fund further research at Mayo in the amount of $1,000,000 per year for 4 years. This research will be in the area of regeneration or protection for cardiovascular applications. These grants will begin in or after
2015, as soon as COMPANY has both had a first commercial sale of a Licensed Product and has had a positive cash flow from operations in the previous financial year. Specific budgets, timelines and deliverables will be part of the research agreement
executed at the time of the grant. 
 Company will have an exclusive right of first negotiation to acquire an exclusive license to any
inventions that are the direct result of work carried out under these grants and that are not already defined as Licensed Inventions (including under sections 5.01 or 5.02). When the research is sufficiently mature to allow the Company to make an
informed decision regarding a license under appropriate terms, Mayo or Company will notify the other party thereof in writing. Company will have 60 days to exercise its option to negotiate as of the date that Mayo has provided Company with all
relevant information and documentation with respect to the invention at issue; if no such interest is shown, then Mayo can license out to a third party. If Company has exercised its option to negotiate, parties during 120 days will expeditiously
seek to negotiate in good faith and execute a reasonable license agreement. This time can be extended in 30 day increments by mutual agreement or in case material new data become available. If parties do not reach agreement within such term, then
Mayo, during the following 9 month period can not enter into a license agreement with respect to the invention with any third party. 
 14.
Change paragraph 5.02 
 5.02 COMPANY DIRECTED RESEARCH. In addition to the research under sections 5.01 and 5.01.01, MAYO will
reasonably assist the Company with research as needed for COMPANY, for example to move towards commercialization and/or to (further) develop existing or new products. In these cases, COMPANY and MAYO will develop a budget and timeline and a list of
specific deliverables. The parties stipulate that this funding will be in the amount of $500,000 per year in 2012, 2013 and 2014. Any amounts not actually spent in any given calendar year will be transferred to the following calendar year and so on.
Any results of this research will automatically fall under the license grant in the Technology License Contract and constitute Licensed Inventions (even if not covered by “Licensed Inventions” as initially defined in the Second Amendment).

 15. Section 6.01 is restated as effective as of the date of this second amendment. 

16. Amend Section 6.02 as follows: add “Except in the circumstances described in Section 3.05.02(c) (“Permitted Disclosures”)(i),
(ii) and (iii), [...]”. 
 17. Replace section 7.01 
 7.01 TERM. The term of this contract is for the longer of ten (10) years, or as long as Mayo has any rights to any part of the Licensed Inventions. 

18. Replace Sections 7.02(c) and 7.02(d) with the following 

  
 5 

 Execution copy 

 

 7.02(c) If the Company defaults in making payment when due and payable or in the making of any
report or if the Company makes a report in which Company made false statements in any material respect (which failure to pay or to report is not remedied within 120 days of receipt of written notice by Mayo, respectively which false statements are
not rectified in a new report within 120 days of receipt of written notice by Mayo) or if the Company makes a report in which Company deliberately made false statements in any material respect, then Mayo (a) on a product-by-product basis (if
the breach relates to a specific product under development or being commercialized) or (b) on a Licensed Invention-by-Licensed Invention basis (if the breach relates to a specific Licensed Invention, but unless the breach relates to a specific
product under development or being commercialized)) may terminate this license. 
 7.02(d) Mayo may notify the Company of its intent to
terminate this license, if the Company at any time after January 2011 has breached its obligation to exercise best efforts as described in Section 8.01. Mayo and the Company will first try to resolve the disagreements in good faith. Should the
disagreements remain, Mayo and the Company agree to binding arbitration as to the existence of the breach of Section 8.01 and Mayo’s right to terminate this license on that basis. In case of arbitration, any termination of this license
will only be effective upon the final decision to that effect of the arbitral tribunal (and then as of the date of such final decision, irrespective of any contractual remedy period that would then still run). Any Arbitration will be carried out
pursuant to Section 10.03bis 
 19. Add section 7.05 
 7.05 DISPUTE RESOLUTION: Parties agree that resolution of any disputes will be negotiated in good faith for a period of 90 days. If the dispute has not been resolved, the Director of Office of
Intellectual Property at Mayo and the CEO of the Company will negotiate for 45 days; the Parties will then attempt non-binding mediation before either can seek relief in court. 
 20. Replace Sections 8.01 and 8.02 with the following 
 8.01 DILIGENCE. The Company commits
to use its best efforts, taking into account all circumstances, to pursue a thorough, vigorous and diligent program of developing (and ultimately commercializing) one or more products making use of a Licensed Invention. Company also represents to
Mayo that all product sold in the United States will be manufactured substantially in the United States. 
 8.02 DILIGENCE. If the
Company at any time during the term of this contract is not exercising its best efforts as described in Section 8.01, then Mayo may notify the Company of its intent to terminate the exclusivity of this contract if Company does not within 120
days of receipt of written notice by Mayo present a plan to Mayo on the basis of which it can be reasonably assumed that the Company will cure its breach of Section 8.01 within a reasonable timeframe. If there is a disagreement regarding whether the
Company has breached Section 8.01 or regarding the plan presented by the Company, then Mayo and the Company will first try to resolve the disagreements in good faith. 

  
 6 

 Execution copy 

 

 
Should the disagreements remain, Mayo and the Company agree to binding arbitration as to the existence of the breach of Section 8.01 and Mayo’s right to terminate the exclusivity on
that basis. In case of arbitration, any termination of exclusivity will only be effective upon the final decision to that effect of the arbitral tribunal. Any Arbitration will be carried out pursuant to Section 10.03bis. 

21. Replace paragraph 9.02 
 9.02
ENFORCEMENT Company shall have the first right, but not the obligation, to defend or enforce the Licensed Patents so long as Mayo is kept informed and given the right and opportunity to advise and comment, provided that such advise and comment
is given within a reasonable timeframe under the circumstances and that Company shall ultimately decide on the course of action. Mayo shall reasonably cooperate in any such action at Company’s expense (reimbursement of pre-approved
out-of-pocket expenses only) but shall not be required to join such action unless it has agreed to do so. Any recoveries or damages shall accrue to the Company. Company shall pay to Mayo 2% of any recovery or damages, net of all costs and expenses
associated with each suit or settlement. 
 22. Replace Section 10.01 
 10.01 ASSIGNMENT AND TRANSFER. With the specific exception of a sale of all or substantially all of a party’s assets (or assets relating to a business line), each party is strictly prohibited
from assigning, delegating or otherwise transferring any of its obligations or rights under this Agreement without the other party’s prior, express and written consent, which consent may not be unreasonably be withheld. Any assignment,
delegation or transfer in contravention hereof is null and void. 
 23. Add “Article 3bis - Option” 

3bis.01 OPTION. Subject to pre-existing obligations and for a period of five years from the effective date of this Second Amendment, Company will
have an exclusive right of negotiation to acquire an exclusive license to any guided cardiopoiesis technology (and the intellectual property rights related thereto) which is either: (i) developed by Andre Terzic M.D.; or (ii) developed or
co-developed by Atta Behfar M.D., and that are not already defined as Licensed Inventions (including under sections 5.01 or 5.02). If, during this option period, any technology is sufficiently mature to allow the Company to make an informed decision
regarding a license under appropriate terms, Mayo will notify the Company in writing. Company will have 60 days to exercise its option to negotiate as of the date that Mayo has provided Company with all reasonable available, relevant information and
documentation with respect to the invention at issue; if no such interest is shown, then Mayo can license out to a third party. If Company has exercised its option to negotiate, parties during 120 days will expeditiously seek to negotiate in good
faith and execute a reasonable license agreement. This time can be extended in 30 day increments by mutual agreement or in case material new data become available. If parties do not reach agreement within such term, then Mayo, during the following
nine month period cannot enter into a license agreement with respect to the invention with any third party. 

  
 7 

 Execution copy 

 

 24. Add Section 10.03bis and delete the final sentence of Section 10.03. 

10.03bis. ARBITRATION. 
 Any dispute
arising out of or in connection with this contract, including any question regarding its termination or any right to terminate, shall be referred to and finally resolved by arbitration under the auspices of the London Court Of Arbitration in
accordance with designated arbitral Rules or Procedures to the extent those Procedures are not inconsistent with the provisions of this paragraph. The parties agree to arbitrate between themselves only; this clause does not permit, and the parties
explicitly reject, class arbitration. Any attempt to involve other parties, whether similarly situated or not, in any arbitration under this contract is a violation of this contract and shall not be permitted. The number of arbitrators shall be
three, one independent and neutral. Within 15 days after commencement of the arbitration, each party shall select one person to act as arbitrator and the two selected shall select a third arbitrator within 15 days of their appointment. The third
arbitrator shall chair the proceedings. The seat, or legal place, of arbitration shall be London, England. The language to be used in the arbitral proceedings shall be English. Within 30 days following the appointment of the arbitrators, each party
shall provide to the other party copies of all documents relevant to the issues raised by any claim or counterclaim. Within 30 days following the date upon which documents are exchanged, the parties may take up to three depositions of up to three
hours each. Discovery disputes shall be resolved upon application to the chair of the arbitration panel; the chair’s resolution shall be final. To the extent not inconsistent with this paragraph, the International Bar Association Rules on the
Taking of Evidence in International Commercial Arbitrations shall be applied. Hearings shall be held on four contiguous dates within 150 days after the arbitrators are appointed, and the Award shall be issued within 200 days after the arbitrators
are appointed. It is the intent of the parties that these time limits be strictly enforced, but they may be extended by agreement of the parties, and failure to adhere to them shall not constitute a basis for challenging the award. The arbitrators
shall agree to comply with this paragraph before accepting appointment. 
 (Remainder of this page intentionally left blank,
execution page follows) 

  
 8 

 Execution copy 

 

			
	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH:
		
	Signed:	 	 /s/ Steven P. VanNurden

	Name:	 	Steven P. VanNurden
	Title:	 	Assistant Treasurer
	
	Date: 18 October 2010
	
	CARDIO3 BIOSCIENCES SA:
		
	Signed:	 	 /s/ Christian Homsy

	Name:	 	Christian Homsy
	Title:	 	CEO and Special Proxyholder
	
	Date: 18 October 2010

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]